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ABSTRACT 
Alkylating agents are one a major class of mutagens contributing to DNA damages and 
carcinogenesis. However, as alkylating agents are powerful inducers of DNA damage related cell 
death, and are commonly used in the chemotherapy. O6-methylguanine (O6meG) and O6-
chloroethylguanine (O6ClethG) are the most cytotoxic lesions caused by Temozolomide (TMZ) and 
1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), respectively. MGMT (O6-methylguanine-DNA 
methyltransferase) repair protein directly reverses O6alkylG lesions and, consequently, it is 
considered as a prognostic marker of resistance in cancer cells exposed to alkylating agents. 
Therefore, expression levels of this protein predict cancer cell susceptibility and the 
success of therapy. However, it has been observed that not all tumors with low MGMT activity 
respond to alkylating agents with increased cell death. Mismatch repair (MMR) system and 
functional status of p53 are also two most relevant factors in this response.  
The aims of this project were to study the genotoxic effects of alkylating drugs as detected 
by the CoMeth assay, and to determine the dependence of a functional MMR system and p53 in 
the sensitivity of cells to treatment. Thus, using a proliferating MMR-proficient cancer cell line 
Caco-2, we report that CoMeth assay allows the qualitative evaluation of O6meG lesions as well as 
O6ClethG, after their conversion to strand breaks. To determine whether the DNA damages 
(comet assay) and cell death (nuclear condensation assay) induced by (TMZ) and (BCNU) agents 
are mediated by MMR we used a MMR-deficient colon HCT116 cell line. We observed that even 
though MMR status seemed to be determinant for cells’ sensitivity to TMZ, this was not applied 
for the case of BCNU. Resistance to the O6-chloroethylating agent involves other mechanisms that 
are independent of functional MMR system. We found that induction of DNA damages by BCNU 
was independent of p53 status, however p53-wt cells showed more pronounced apoptosis 
compared with p53-null cells.  
Altogether, our data show that functional MMR system is required for genotoxicity 
(apoptosis) induced by TMZ. For BCNU, we show that the efficiency on cancer cells is not 
dependent on the MMR status but only the activity of MGMT. In p53-wt cells, cell death by BCNU 
was more pronounced. This project also demonstrated the value of the CoMeth assay as a tool 
for the study of anticancer chemotherapeutic drugs.  
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RESUMO 
Agentes alquilantes são uma das maiores classes de mutagénicos contribuindo para os 
danos no DNA e para a carcinogénese. Contudo, como os agentes alquilantes são indutores 
potentes de danos no DNA relacionados com a morte celular eles são frequentemente usados na 
quimioterapia. O6-metilguanina (O6meG) e O6-cloroetilguanina (O6-cletG) são as lesões mais 
citotóxicas causadas pela Temozolomida (TMZ) e 1,3-bis-(2-cloroetil)-1-nitrosureia (BCNU), 
respetivamente. MGMT (O6-metilguanina-DNA metiltransferase) repara a proteína e reverte 
diretamente as lesões O6-alquilG e, consequentemente, é considerado um marcador de 
prognóstico de resistência em células cancerígenas expostas a agentes alquilantes.  
Desta forma, os níveis de expressão desta proteína preveem a suscetibilidade das 
células cancerígenas e o sucesso da terapia baseada em agentes alquilantes. Contudo, tem sido 
observado que nem todos os tumores com baixa actividade da MGMT respondem a agentes 
alquilantes com morte celular aumentada. O sistema de reparação Mismatch repair (MMR – do 
inglês mismatch repair) e o estado funcional do p53 são também dois dos fatores mais 
relevantes nesta resposta.  
Os objetivos deste projeto foram estudar os efeitos genotóxicos de drogas alquilantes, 
sendo detetadas pelo ensaio do Cometa e determinar a dependência do estado funcional do 
sistema Mismatch repair e do p53 na sensibilidade às drogas alquilantes. Desta forma, usando 
uma linha celular cancerígena proliferativa Caco-2, com um sistema MMR eficiente, 
demonstramos que o ensaio do Cometa permite uma avaliação qualitativa das lesões O6meG 
bem como as O6-cletG, depois da sua conversão em quebras na cadeia de DNA. Para determinar 
se os danos no DNA (ensaio do cometa) e morte celular (ensaio de condensação nuclear) 
induzidos pelos agentes metilantes (TMZ) e cloroetilantes (BCNU) são mediados por reparação 
MMR usamos a linha celular HCT116 deficiente no sistema MMR. Observamos que apesar do 
estado MMR parecer ser determinante para a sensibilidade das células à TMZ, este facto não foi 
observado para o caso do BCNU. A resistência ao agente O6-cloroetilante envolve outros 
mecanismos que são independentes do sistema funcional MMR. Verificamos que a indução dos 
danos no DNA pelo BCNU foram independentes do estado do p53, contudo as células com p53 
ativo apresentaram uma apoptose mais pronunciada comparado com as células com p53 
inativo. De um modo geral os nossos resultados mostram que o sistema funcional MMR é 
necessário para a genotoxicidade (apoptose) induzidos pela TMZ. Para o BCNU, mostramos que 
a eficiência nas células cancerígenas não é dependente do estado do MMR mas apenas da 
actividade da MGMT. Nas células com p53 ativo a morte celular induzida pelo BCNU foi mais 
pronunciada. 
  viii  
  
Este estudo também demonstrou o papel do ensaio do cometa como ferramenta no 
estudo de drogas anticancerígenas.   
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Figure 1.1 – The tem hallmarks of cancer proposed in 2011 by Hanahan and Weinberg (Adapted from (Hanahan 
and Weinberg, 2011). 
Cancer are the most health problem and are the leading cause of death in economically 
developed countries. This problem arises as a consequence of population aging and adoption of 
cancer-associated behaviors including smoking, alcohol and diets (Jemal et al., 2011). Even 
though the advance, over the years, in treatment strategies, such as surgery, radiotherapy and 
chemotherapy, it is estimated that, in 2008, 12.7 million new cancer cases and 7.6 million 
cancer related deaths occurred (Ferlay et al., 2010). 
The process of carcinogenesis is highly complex and comprise a set of interactions 
between molecular (genetic and epigenetic) and environmental factors. Tumorigenesis is 
originated through one or more mutations that occur in a cell, giving them a selective advantage 
by enabling it to grow under conditions of limitation of nutrients, oxygen and/or growth factors. 
These cells, through a selection process, are capable of multiplying and invading large regions of 
the organism. These abnormal cellular features acquired during tumor development are known 
as the hallmarks of cancer (Hanahan and Weinberg, 2011). This ten proposed hallmarks 
including sustained proliferative signaling, resistance to cell death, replicative immortality, 
stimulation of angiogenesis, evasion from immune destruction, genome instability and mutation, 
deregulation of cellular energetics, promotion of tumor inflammation and evasion from growth 
suppressors (Figure 1.1). 
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Through to genetics analysis of tumors it was possible identify two types of genes: the 
oncogenes, which are the capacity to potentiate the tumorigenesis, and tumor suppressor genes, 
that are responsible for protecting the cells against any event that promote the transformation of 
a normal cell into a neoplastic cell.  
Studies in several cancers revealed that abnormalities in twelve pathways or regulatory 
processes can lead to cancer progression such as: DNA damage control, apoptosis, regulation of 
G1/S phase progression, cell adhesion, c-Jun N-terminal kinase signaling, integrin signaling, 
KRAS signaling, small GTPase-dependent signaling, regulation of invasion, Wnt/Notch signaling, 
TGF-β signaling and hedgehog signaling (Gerstung et al., 2011; Jones et al., 2008). 
Nonetheless, only the broad knowledge of pathways which has a role in tumorigenesis, will 
allow the design of new therapies that can offer a higher survival for patients.  
1.1. Colorectal carcinoma (CRC) 
Due to the high regeneration ability of the intestinal epithelium, processes such as 
proliferation and apoptosis are very important to maintain homeostasis, and consequently 
deregulation of these mechanisms in addition of other mutations can lead to colorectal cancer 
(CRC) development (Araújo et al., 2011).  
Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second in 
women. According to GLOBOCAN 2008, the world age-standardized incidence rate (ASR) of this 
cancer is substantially higher in men than in women (20.3 vs. 14.6 per 100,000 people, 
respectively).This tendency is also verified in Europe (37.4 in men vs. 23.9 in women) and in 
Portugal (40.6 in men vs. 24.1 in women). These tumors are more incident in developed 
countries than in developing countries. This cancer is also characterized by high mortality rates 
(Globocan, 2008). 
The CRC tumors are divided in two subclasses:  hereditary or sporadic. The most common 
type of CRC is the sporadic cancer and, in this case, risk factors include lifestyle (e.g. physical 
inactivity and obesity), environmental factors (such as excessive alcohol consumption and 
smoking, high consumption of red meat) and age and most patients being over 50 years old 
(Berlau et al., 2004; Jemal et al., 2011; Souglakos, 2007). Only around 20% of the total cancers 
are hereditary, and the most common are the Lynch syndrome (also called as hereditary non-
polyposis colorectal cancer (HNPCC)) that is caused by germiline mutations in mismatch repair 
(MMR) system. The loss of functional MMR system in Lynch syndrome patients occurs due to the 
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epigenetic silencing of genes involved in this pathway (by DNA methylation) as well as by 
mutations in MMR genes (Markowitz and Bertagnolli, 2009). 
 The syndrome familial adenomatous polyposis (FAP) is the other example of hereditary 
colorectal cancer and results from germiline mutations in APC (adenomatous polyposis coli) gene 
(Souglakos, 2007). 
The accumulation of mutations in several genes such as tumor suppressor genes, and 
oncogenes occurs often in CRC but also in other tumor types (Futreal et al., 2004). In CRC, a 
sequence of events has been described in several genes that promote the development of CRC. 
The mutation in the tumor suppressor gene APC, which is not only responsible for hereditary 
cancer but also plays a role in sporadic tumors, represents the most common mutation in the 
early phase of CRC development. This gene is responsible for controlling the WNT signaling 
pathway and controls specific proteins involved in this signaling such as β-catenin. Loss of 
function mutations in the APC result in the nuclear translocation and accumulation of β-catenin 
where it will be promote the activation of several transcription factors involved in proliferation and 
differentiation processes in the intestinal crypt epithelial cells. Other frequent mutation occur in 
the KRAS gene and happens during later phases of tumor progression (Vogelstein and Kinzler, 
2004). Mutations that affect KRAS lead to unregulated cell proliferation and, consequently, the 
malignant transformation since leads to the constitutive activation of this pathway. The mutation 
in TP53 gene is another preponderant alteration found in CRC and occurs during the late phase 
of CRC development. This mutation occurs in approximately 50% of CRC. The p53 transcription 
factor is a transcriptional regulator of genes that are involved in cell cycle, regulating apoptosis 
and DNA repair. As a consequence, p53 mutations facilitate ilimited growth and apoptosis 
evasion (Fearon, 2011). 
As referred above, genetic alterations in genes that encode enzymes belonging to MMR 
system also have a crucial impact in CRC. Nearly 10-15% of sporadic cancers exhibit mutations 
in MMR genes. Malignant transformation is facilitated by the presence of these mutations since 
this allows the accumulation of DNA damages. The genetic instability detected in CRC may arise 
by from two pathways: chromosomal instability (CIN) and microsatellite instability (MSI). The CIN 
pathway causes allelic losses, chromosomal translocations and amplifications (Redston, 2001; 
Söreide et al., 2006). Microsatellite instability pathway, MSI, occurs in approximately 15% of 
CRC. Microsatellites are frequently found in whole DNA sequence and are constituted by 
repeating sequences of nucleotides. Therefore, MSI is a condition in which a microsatellite allele 
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Figure 1.2 - Schematic representation of some genetic alterations during the evolution of colorectal cancer 
(Adapted from (Walther et al., 2009). 
loss or gains repeated sequences in chromosomal regions. MSI is due to mutational or epigenetic 
silencing of MMR genes (Fearon, 2011). This way, the detection of defects in MMR system is one 
of the most promising biomarkers in CRC. MSI has been found in several cases of sporadic 
cancer where it is mainly due to epigenetic silencing caused by methylation of CpG islands 
presents in MLH1 promoter gene (approximadetly 95% of the cases) (Markowitz and Bertagnolli, 
2009). In turn, in hereditary colorectal cancer the instability in microsatellite sequences is 
caused, frequently, by mutations in some mismatch repair genes such as, hMSH2, hMLH1 and 
hMSH6 (Söreide et al., 2006) (Figure 1.2). With regard to MSI CRC may be subdivided in three 
MSI phenotypes: microsatellite stable (MSS, none sequences affected), MSI high (MSI-H, at least 
40% of loci are affected) and MSI low (MSI-L, a single locus is affected) (Fearon, 2011).  
 
In CRC, the survival rates have significantly improved since there has been an increase in 
the knowledge about the prevention/ risk factors, early detection and therapy.  
It has been estimated that it is necessary a long period of time (approximately 10-17 
years) for colon cancer development because requires several mutations, as referred above.  This 
lag time provides an opportunity to early detection and for development of prevention strategies 
(Chen and Huang, 2009). 
In terms of treatment of CRC, great advances have been made that allow increasing the 
survival from 6 months to 2 years. After surgical removal of the tumor, the treatment is mainly 
based on chemotherapy with 5-Fluorouracil (5-FU), however some resistance to this drug have 
been reported in several cases. Therefore, to overcome this problem other drugs mainly 
irinotecan and oxaliplatin are used in combination with 5-FU. More recently, monoclonal 
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antibodies (such as, cetuximab and panitumumab) have been developed with the aim to inhibit 
specific targets involved in tumoral proliferation (for instance, epithelial growth factor receptor - 
EGFR) (Bhushan et al., 2009; Davies and Goldberg, 2008). 
1.2. DNA damages and genomic stability   
The integrity and stability of the DNA double helix is essential for the normal function of 
organisms. However, DNA is constantly exposed to modifications from a variety of damaging 
agents, of both endogenous and exogenous sources. The majority of endogenous damages is 
caused by cellular metabolites (such as reactive oxygen species – ROS and replication errors), 
while exogenous sources of DNA damaging agents comprise ionizing radiation, toxins, ultraviolet 
light and pollutants or, in cancer patients, chemotherapeutic drugs.  
The major type of alterations in DNA induced by alkylating agents may cause single- or 
double-strands DNA breaks (SSB and DSB, respectively), crosslinks (intrastrands or interstrands - 
ICls) formation of apurinic/apyrimidinic (AP) lesions (also known as abasic sites), base 
modifications (such as alkylated bases), and DNA-protein crosslinks (Figure 1.3) (Maynard et al., 
2009; Spry et al., 2007). Cell death and aging are examples of some events that result from 
these alterations in the genome. 
In mammalian cells, there are some cellular responses that may be activated by DNA 
damages, referred above, in order to remove the toxic effects of the anticancer agents. These 
responses include: 1) activation of DNA checkpoints for modulation of cell cycle progression 
allowing the repair of the damages and prevents the transmission of the lesion; 2) induction of 
cell death allowing the elimination of damage or deregulated cells; 3) transcriptional response 
causing modifications in transcription levels of certain genes (verifying the up- or downregulation 
of genes) and 4) induction of DNA repair pathways for complete removal of DNA damages. 
Collectively, these cellular responses determine whether cell survive or goes into cell death by 
apoptosis (Madhusudan and Middleton, 2005).    
Therefore, repair and protection of DNA are two key mechanisms very important in the 
prevention of several pathologies including cancer (Sancar et al., 2004; Spry et al., 2007). 
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Figure 1.3 – Representation of common DNA damaging agents and respective DNA lesions induced by these 
agents (Adapted from (Hoeijmakers, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
1.3. Alkylating agents 
Even though oxidative damages are the most studied, DNA alkylation damages have also a 
critical role in cancer development and treatment. Alkylating agents represent a ubiquitous family 
of chemicals that react with several biomolecules by transfer of alkyl groups causing alteration in 
the structure and the function of these molecules. 
Alkylating agents may be present either in the environment or inside cells. Potential 
exogenous sources comprise contaminants (such fuel combustion, tobacco smoke) and the 
heterocyclic amines existent in food, while endogenous sources derived from such as 
subproducts of oxidative stress (Drabløs et al., 2004; Fu et al., 2012; Wirtz et al., 2010). 
Alkylating agents are able to react with oxygen (O) and ring nitrogen (N) present in DNA 
nitrogenous bases. DNA lesions created by alkylating agents are determined by their: chemical 
reactivity (SN1-type or SN2-type nucleophilic substitution), amount of reactive sites (designated as 
monofunctional or bifunctional), alkyl group added (methyl, chloroethyl, etc) and the DNA 
substrate (single or double stranded) (Fu et al., 2012).  
The range of DNA lesions that can be created by the action of alkylating agents include, O-
alkylated lesions (e.g. O6-methylguanine (O6meG) and O4-methylthymine (O4meT)) and N-alkylated 
lesions (e.g. N7-methylguanine (N7meG) and N3-methylguanine (N3meG)).Even though alkylation in 
the atoms of oxygen are produced in much smaller amounts than N-alkyl lesions, O-alkyl lesions 
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have a great biological significance since theses lesions, during DNA replication, can cause highly 
genotoxic and mutagenic effects. Generally, N-alkylations are less mutagenic since are rapidly 
removed by base excision repair (BER) or the AlkB homologue (ALKBH) (Boysen et al., 2009; 
Kondo et al., 2010b). The elevated reactivity of the N-atoms leads to that this alkylation 
represents over 80% of alkylated bases. For instance, N7meG is a very common methylation 
comprising 60-80% of the total alkylation lesions in molecule of DNA. N3meA and N3meC 
comprise 10-20% of the total methyl damages. Of total DNA adducts, O6-methylguanine is present 
only in 8% (after methylnitrosourea exposure, MNU) and in 0.3% (after methyl methanesulfonate 
exposure, MMS). O4meT is less abundant in the DNA and, until now, little is known about its 
mutagenicity and cytotoxicity (Fu et al., 2012; Kondo et al., 2010b).  
Due to their carcinogenic and cytotoxic properties, the alkylating agents are considered 
dangerous to human health. However, some of compounds are commonly used as 
chemotherapeutic drugs in order to kill cancer cells. Although alkylating agents contribute to the 
onset of cancer, they also play a relevant role in the treatment of cancer (Fu et al., 2012). Most 
of the anticancer alkylating drugs used are monofunctional methylating agents (e.g. 
temozolomide [TMZ] and N-methyl-N’-nitro-N-nitrosoguanidine [MNNG]) containing only one 
active chemical group for the alteration of a single site in DNA. The TMZ and MNNG are the SN1-
methylating agents because they alkylate not only nitrogen but also oxygen groups in DNA bases. 
Contrarily, compounds such as methyl methanesulfonate (MMS) belongs to SN2-methylating 
agents because mainly alkylate nitrogen rings. Bifunctional alkylating agents (such as nitrogen 
mustards, e.g. cyclophosphamide and chlorambucil) and chloroethylating nitrosoureas (e.g. 
carmustine [BCNU], nimustine [ACNU] and fotemustine) contain two reactive sites and can 
interact with separate bases present in opposite DNA strands culminating in the formation of 
interstrand crosslinks (ICLs) in addition to monoadducts and intrastrand crosslinks (ligation 
between two nucleobases in the same DNA strand). The chloroethylating agents have the ability 
to add a chloroethyl group to nucleobases (Deans and West, 2011; Fu et al., 2012; Kondo et al., 
2010b). Among all DNA lesions produced by these drugs ICLs are particularly toxic and lethal to 
cells because they inhibit the separation of the two strands of DNA and, consequently, block 
replication forks affecting replication and transcription processes (Deans and West, 2011). The 
mispair between O6meG and thymine may also originate cytotoxic breaks when recognized by the 
MMR system. 
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Overall, chemotherapeutic alkylating compounds have the ability to change a range of 
biomolecules including DNA generating damages that may cause cell death by apoptosis, and 
therefore can be useful in the treatment of cancer (Fu et al., 2012).  
The standard treatment applied in cancer patients is based on surgical resection followed 
by radiotherapy and chemotherapy in order to remove residual cancer cells. Over the years, 
chemotherapeutic alkylating agents (with methylating or chloroethylating properties) have 
received much attention in the treatment of several cancers such as melanoma, ovarian cancers 
and lymphomas. For instance, Dacarbazine was approved by FDA (with methylating properties) 
due to its efficiency for treatment of melanoma after surgical resection (Gerson, 2004).  
Alkylating anticancer drugs are widely used in glioblastoma patients. The main reason for 
application in this type of tumors is due not only their ability to easily cross the blood-brain barrier 
but also their efficient absorption after administration. First, only nitrosoureas chemotherapeutics 
(such as CCNU and BCNU) were approved and applied for the therapy of glioblastomas. 
However, these agents only offered a small improvement in the quality of life of these patients 
(Rhee et al., 2009). To attempt to overcome this problem, more recently, TMZ was implemented 
as standard chemotherapeutic drug for this type of cancer because an enhancement in median 
survival of patients was observed. Some studies, mainly in glioma patients, also demonstrated 
that the addition of chemotherapy based on alkylating agents to radiotherapy prolongs the 
median of survival compared with patients subjects only a radiotherapy (Stupp et al., 2005). 
Therefore, the concomitant and adjuvant application of alkylating chemotherapeutic agents after 
surgical resection have been applied in some solid tumors and are a good strategy that provides 
survival benefits. 
1.4. Mechanism of DNA repair 
As above mentioned alkylating agents can promote the development of many kinds of DNA 
alkylated base lesions and normally, organisms respond by repairing the damage through to 
several pathways and, consequently, preventing genomic instability. The most important DNA 
repair systems that are involved in repair of alkylation damages include: mismatch repair (MMR), 
base excision repair (BER), nucleotide excision repair (NER), homologous recombination (HR) 
and non-homologous end joining (NHEJ) pathways (Hoeijmakers, 2001).The repair of DNA 
alkylating damages also can be executed by O6-methylguanine-DNA methyltransferase repair 
protein (MGMT) through direct repair without removal of the damage base (Helleday et al., 
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2008). Collectively these pathways are major players in modulation of cell sensitivity to alkylating 
agents. It is thought that these repair pathways are interconnected and although they can be 
defined separately, they perform functions that overlap with each other (Knudsen et al., 2009). In 
order to maintain the genome stability, cells developed a network of pathways (which constitute 
the DNA damage response (DDR)) that allow the detection of DNA lesion, signals its presence 
and stimulate its repair. In mammalian cells, ATM (ataxia-telangiectasia mutated) and ATR (ataxia 
telangiectasia and Rad3-related protein) protein kinases (members of the phosphatidylinositol 3-
kinase (PI3K) superfamily) are main components this signaling network. ATM are recruited and 
activated by DSBs, whereas ATR has been associated in response to diverse types of DNA lesions 
such as DSBs, crosslinks, monoadducts, SSBs as well as stalled replication forks (Cimprich and 
Cortez, 2008; Jackson and Bartek, 2009). The two direct targets of these kinases are the protein 
kinases CHK2 (checkpoint kinase 2) and CHK1 (checkpoint kinase 1), respectively (Bartek and 
Lukas, 2003). Consequently, these activation may promotes the cell cycle arrest allowing more 
time for repair the DNA before replicative process (Jackson and Bartek, 2009). In response, for 
example, to cytotoxic O6-alkylG DNA adducts induced by alkylating agents occurs the ATR 
activation. In this case, ATR promotes the phosphorylation and activation of CHK1 and p53 that 
in turn trigger apoptotic pathways and cell cycle arrest. For instance, the SN1 –type alkylating 
agents induced arrest in the G2/M phase of cell cycle and posteriorly apoptosis in the second 
cell cycle after treatment and these events were preceded by activation of ATR and 
phosphorylation of CHK1 and p53 (Yoshioka et al., 2006).  
1.4.1. Direct damage reversal repair 
The main mechanisms that support the repair of alkylated lesions comprise the O6-
methylguanine-DNA methyltransferase (MGMT) protein. MGMT operates in cells in order to inhibit 
the effects of chloroethylating and methylating agents and repairs O6-alkylG lesions (Kaina et al., 
2010). MGMT is described as DNA suicide enzyme that supports the elimination of the methyl or 
chloroethyl group linked in the O6 position of guanine and, this group, is transferred to the 
cysteine residue present in the catalytic site of MGMT. This reaction is irreversible and culminates 
in inhibition of the protein that, posteriorly, undergoes ubiquitination and degradation in the 
proteasome (Figure 1.4) (Verbeek et al., 2008).  
Therefore, the repair capacity of O6-alkylG is mainly determined by the number of active 
MGMT molecules presents in the cells (Kaina et al., 2010). Lesions like O6meG are considered 
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Figure 1.5 - Action mechanism of the MGMT system (Adapted of Kaina et al., 
2010). 
Figure 1.4 - Representation of the repair reaction by MGMT molecule (Adapted from (Kaina et al., 2010)). 
highly mutagenic, and if MGMT is not enough to remove all lesions, during replication this lesion 
may interact with thymine rather than cytosine causing GC-AT transitions (Eker et al., 2009). 
 
 
 
 
 
 
 
 
However, for a long time it was not understood how this type of lesion, that does not stall 
DNA replication, can be highly cytotoxic. After some studies realized in cells defectives in MMR 
pathway it was observed that the cytotoxicity of the O6-meG is mainly due to the recognition of 
mispairs by the MMR pathway (Levati et al., 1998; Liu et al., 1996; Quiros et al., 2010).  
 
This system promotes the elimination of the thymine existent in complementary strand 
creating a break and, consequently, getting the O6MeG free to pair once more with another 
thymine in the next round of DNA replication. So, if O6MeG remains in the strand, this leads to 
the repetition of the process triggering a futile cycle of repair. This cycle can culminate in 
chromosomal aberrations, cell cycle arrest or in the formation of DSBs that are powerful 
activators of apoptosis (Figure 1.5) (Bugni et al., 2009; Kaina et al., 2007). Due to formation of 
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DSBs caused by repetitive MMR processing, homologous recombination pathway (HR) can 
constitute another cellular mechanism against the cytotoxicity caused by O-alkyl adducts. In 
support of this, cells HR-deficient display an enhanced in sensitivity to O6-alkylating agents (Roos 
et al., 2009). Besides of O6meG lesions, MGMT can also promote the removal of primary adducts 
induced by chloroethylating agent (O6-chloroethylguanine - O6-ClethG). This way, the chloroethyl 
group attacks the O6 position of guanine forming an optimal subtract for direct repair by MGMT 
(Drabløs et al., 2004).   
MGMT have particular interest for cancer research due to its role in cancer prevention and 
cancer chemotherapeutic response. Therefore, MGMT promote the removal of O6-alkylG adducts 
from DNA template induced by exogenous or endogenous compounds provides protection of 
normal cells. However, if levels of MGMT expression were elevated in cancer patients, this would 
lead to also the protection of tumor cells against chemotherapeutic agents since it was occurred 
the efficient elimination of O6-alkylG lesions induced by these drugs.  
It has been described that 50% of these cancers exhibit methylation of the CpG islands 
present in the MGMT promoter region leading to epigenetic silencing of MGMT gene and 
inhibition of ability to repair O-alkyl lesions from DNA (Lind et al., 2004). This methylation, which 
promotes the formation of inactive chromatin, occurs frequently in glioblastomas, head and neck 
carcinomas and has been observed in the early phases of carcinogenesis (Esteller et al., 2000). 
Thereby, the status of the MGMT promotor is recognized as a prognostic factor for therapy since 
absence of MGMT expression is considered a positive survival predictive marker in patients who 
are treated with alkylating chemotherapeutics (Liu and Gerson, 2006; Verbeek et al., 2008). In 
addition to promoter methylation there are other factors that influencing MGMT expression 
including transcription factors. The sequence of MGMT promoter contains many transcription 
binding sites such as glucocorticoid response element. Thus, induction of these sites results in 
enhances in MGMT expression, which are enough to cause more resistance to alkylating 
therapies. Dexamethasone, a synthetic glucocorticoid, is one example of a compound that 
capable to upregulate MGMT in vitro and reduces the efficiency of chemotherapy (Biswas et al., 
1999). All of these facts support the view that chemical depletion of MGMT activity could be used 
to sensitize tumor cells to alkylating drugs. Therefore some strategies have been developed in 
order to enhance the response to these agents. One of the most potent inhibitors of MGMT 
activity is O6-benzylguanine (O6-BG) and has been applied in many studies realized in vitro and in 
vivo (Dolan et al., 1991; Kreklau et al., 1999; Rhines et al., 2000). The low molecular weight 
1. Introduction 
 
 14  
 
compound operates as a substrate for MGMT and this reaction leads to irreversible inhibition of 
the MGMT protein (Rabik et al., 2006). Due to its effectiveness, this compound have been used 
in combination with therapy based on alkylating agents and has shown promise in clinical trials 
with patients with glioblastoma (Quinn et al., 2009; Weingart et al., 2007). Unfortunately, the 
systematic application of O6-BG and consequently, depletion of MGMT activity concomitantly with 
alkylating agents not only affects the tumor cells but also normal tissue cells can lead to 
myelosuppression (Fu et al., 2012). Therefore it is desirable to develop approaches for the 
specific targeting the MGMT-inhibiting agent to the tumor. One of the strategies, which have been 
done in patients with glioblastoma multiforme, is the local intracerebral administration of the 
inhibitor (Koch et al., 2007). To attenuate the myelosuppression, gene therapy may provide 
protection of bone marrow cells against the collateral toxicity of chemotherapeutic agents. 
Human MGMT cDNA enconding P140K or G156A are mutant versions of MGMT that are very 
resistant to inhibition by O6-BG, that, ita transplanted into bone narrow will ensure high levels of 
expression of MGMT (Kaina et al., 2010; Verbeek et al., 2008). In conclusion, the modulations of 
MGMT concomitantly with alkylating agents together with strategies that protect stem cell are 
clearly approaches that could trigger major advances in therapy based on alkylating agents. 
1.4.2. Mismatch repair  
One of the DNA repair mechanisms that acts after replication is the mismatch repair 
(MMR) and it promotes the elimination of base-base mismatches which are made by DNA 
polymerases as well as insertion-deletion loops (IDLs) (Kunkel and Erie, 2005). In addition to the 
repair of the damages mentioned above, this system has a major impact on the level of damages 
caused by alkylating agents (such as TMZ) since can also mediates a O6meG-induced cellular 
response. The O6meG lesions that may mispair with thymine present in the complementary 
strand leads to the formation of O6meG:T mismatches. These adducts are efficiently recognized 
by MMR system through to the MutSα heterodimer. Then, MMR, by the action of several proteins 
as will be described below, can promotes the removal of thymine from template creating a SSBs 
(Kaina et al., 2007; Martin et al., 2010). It is important noted that some studies referred that 
MMR system is only relevant in cases of treatment based on methylating agents contrary to 
chloroethylating agents and, this system acts after one cycle of replication (Kaina et al., 2010). 
However, this question needs to be clarified. 
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The MMR system targets the newly synthesized strand unlike NER and BER systems. In 
this pathway, two heterodimers are responsible for the recognition of the damage and initiation of 
repair: the hMutSα (which is constituted by MSH6 and MSH2 and recognizes base mismatches 
and small IDLs containing between one or two extrahelical nucleotides) and hMutSβ (a dimer of 
MSH3 and MSH2 responsible for the recognition of larger IDLs). The machinery of excision 
depends on the complex of MutSα, MutLα, exonuclease-1 (Exo1) and replication protein A 
(Kreklau et al., 1999). Therefore, through interaction between them the excision of the mismatch 
is stimulated and Exo-1 promotes the degradation of the strand in a 5’-3’ direction. The RPA will 
stabilize the region of single-strand DNA. After ablation of the damage the activity of EXO-1 is 
inhibited by MutLα and the Pol δ/PCNA complex fills the break with complementary nucleotides 
and through the action of DNA ligase I the incision is closed (Jiricny, 2006) (Figure 1.6).  
According to the current studies, proteins involved in mismatch repair have the ability to 
recognize DNA damage and signal to the cell cycle checkpoint directly, which can cause 
apoptosis and cell-cycle arrest. On the other hand, this mechanism can try unsuccessful remove 
the damage causing stall of replication forks. In this case, the SSBs will promote the recruitment 
of RPA and ATR-interacting protein (ATRIP). These proteins cause the activation of ATR kinase 
which in turn phosphorylates kinase CHK1. It has been described that cells deficient in hMutSα- 
and hMutLα fail to arrest cell-cycle when exposed to several types of DNA-damaging agents (Li, 
2008).  
 It has been described that MMR-deficient cells are less sensitive to death induced by 
several types of chemicals (such as SN1-type methylating agents) than cells with functional MMR 
system (Stojic et al., 2004). One explanation for this fact is that cells without MMR, in response 
to DNA damage, cannot phosphorylate p53 and p73 and this implicates ATR and ATM since 
these kinases are responsible for the phosphorylation of p53 and p73 (Li, 2008). It has been 
demonstrated that hMutSα and hMutLα are responsible for the recruitment of ATR-ATRIP to sites 
of damages, by physical interaction, in cells submitted to treatment with DNA damaging agents 
and, this way, MMR proteins are implicated in a signaling cascade that triggers cell cycle arrest 
and apoptosis (Yoshioka et al., 2006).   
Several reports have helped to understand that MMR mechanism have significant impacts 
on the outcome of cancer therapeutic interventions. 
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Figure 1.6 – Representation of mismatch repair pathway (Adapted from Genetex). 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3. Base excision repair  
Among the DNA repair pathways the base excision repair (BER) is one of the most highly 
conserved and occurs both in the nucleus and in mitochondrial DNA. This process identifies and 
repairs several damages including: SSBs and base lesions that arise due to oxidation (e.g. 8-
hydroxyguanine (8-oxoG) or formamidopyrimidines), alkylation (N7-alkylguanine, N3-alkylguanine) 
or deamination and AP sites (Maynard et al., 2009). The first step of this process is the 
recognition of the damaged base by a DNA glycosylase which catalyzes the cleavage of the N-
glycosidic bond (between the sugar and the base) forming an apurinic/apyrimidinic site (AP site). 
The DNA glycosylases is specific for the DNA lesion (e.g. in response to oxidative damage 
operates mutY homologue (MYH), Endonuclease III (NTH), human endonuclease VIII-like 1 (NEIL) 
and 8-oxoG-DNAglycosylase (OGG1); and in alkylating lesion are recognized by N-methylpurine-
DNA glycosylase (MPG)) (Knudsen et al., 2009; Robertson et al., 2009). The cleavage of the AP 
site is carried out by the apurinic/apyrimidinic endonuclease (APE1) giving rise to 5’deoxyribose 
phosphate (dRP) and 3’OH ends. Then, the DNA polymerase β (Polβ) will add a complementary 
nucleotide to fill the gap. To finish the process, a DNA ligase seals the incision (Figure 1.7) 
(Hegde et al., 2008). BER can be sub-divided into two divergent pathways depending on the 
location (active or inactive regions of the genome) as well as nature of the lesion. When only one 
nucleotide is removed, this process occurs by short-patch BER (SP-BER), however, during long-
patch BER (LP-BER) about 2-6 nucleotides are integrated at the damaged site (Maynard et al., 
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Figure 1.7 – Representation of base excision repair pathway (Adapted from Genetex). 
2009). Some targets of alkylating agents (such as temozolomide and carmustine) are the N-
residues of purines and pyrimidines. The N-alkylpurines (such as N7-alkylG, N3alkylG and N3-
alkylA) are mainly repair through BER pathway and the DNA adducts are recognized by MPG 
glycosylase promoting its removal from DNA strand (Roos et al., 2009).  
Several studies have demonstrated that this repair pathway is connected with cancer. It 
has been established that defects in proteins involved in BER pathway cause an increased risk of 
numerous types of cancer including colon cancer (Wilson and Bohr, 2007). Some lesions, like 
3meA, are very mutagenic and toxic for normal cells and it is essential that this pathway is 
functional in order to avoid an accumulation of these toxic lesions leading to development of 
cancer. These defects, on the other hand, can be crucial for treatment of cancer. For example, 
cancer cells with defects in Polβ are more sensitive to MNNG and TMZ and consequently 
increasing the cytotoxic effect of alkylating chemotherapeutic agents (Sobol et al., 1996). 
Currently, some clinical are under development with the aim to potentiate the downregulation of 
BER or modulate enzymes involved in this pathway in order to increase alkylating drug sensitivity. 
So, small-molecule inhibitors of Pol β, inhibitors of APE activity and chemical modulation of poly 
(ADP-ribose) polymerase (PARP) are some examples of strategies applied in cancer cells (Bapat 
et al., 2010; Mégnin-Chanet et al., 2010; Wilson et al., 2010).  
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1.4.4. Nucleotide Excision Repair 
 In the organism, the most versatile mechanism of DNA repair is the nucleotide excision 
repair (NER), which can identify and repair several DNA lesions. Cyclobutane pyrimidine dimers 
and (6-4)-photoproducts are lesions often created by ultraviolet light and that are processed by 
this pathway. Besides these damages, the NER pathway also contributes to the elimination of 
damage produced through the action of alkylating agents (e.g. interstrand crosslinks-ICLs) 
(Hanawalt, 2002; Kondo et al., 2010b). All these adducts are very cytotoxic for cells and change 
the normal structure of DNA affecting processes such as replication or transcription. NER can be 
categorized into two different pathways: global genomic repair (GGR, which processes injuries in 
the whole genome, including non-transcribed strands) and transcription coupled repair (TCR, 
which operates in the transcribed DNA strands). NER pathway comprises numerous steps such 
as: lesion recognition and structural distortion of the DNA (by XPC-HR23B-Cen2 complex); 
denaturation, nearly 30 nucleotides, of the strand around the damage (Transcription factor II 
human (TFIIH)); incision of the damaged (XPG in 3’end and ERCC1-XPF in 5’ terminus); removal 
of lesion and the break is closed by the DNA polymerase and the ligation of the nick occurs by 
action of the DNA ligase III (Figure 1.8) (Nouspikel, 2009). 
Like BER, also NER play an important role in treatment of cancer mainly if the patients 
receiving treatment based on the alkylating agents that promote the formation of ICLs. For 
example, several studies demonstrated that, patients with ERCC1 negative cancers that received 
adjuvant chemotherapy have a better prognosis and are more sensitive to alkylating agents 
(Olaussen et al., 2006).  
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Figure 1.8 – Representation of nucleotide excision repair pathway (Adapted from Genetex). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.5. Homologous recombination and non-homologous end-joining repair 
The DNA double-strand break is one of the most lethal lesions in human cells that can 
provoke genetic instability or cell death. Owing to these consequences the cells developed two 
distinct pathways that may be used for its repair: homologous recombination (HR) and non-
homologous end-joining (NHEJ) (Ohnishi et al., 2009). Despite of alkylating agents do not have 
the ability to induce directly DSBs, these type of lesion are identified  in a final event after the 
treatment of cancer cells with methylating and chloroethylating agents (Kondo et al., 2010a; 
Kondo et al., 2009). The great difference between them is that HR uses DNA sequence homology 
to promote the DNA repair. HR requires the presence of an undamaged homologous DNA 
sequence (sister-chromatid) that serve as a template allowing repair the missing sequence at the 
DSB site. On the other hand, NHEJ is a simplest mechanism that also promotes the DSBs repair 
and, in this case, it observed a re-ligation of damaged DNA ends without needing a template 
(Dudáš and Chovanec, 2004). This mechanism is more important essentially for the removal of 
DSBs during the G1-phase of cell cycle because HR is not proficient owing to the absence of a 
homologous sequence. Contrary to HR system, NHEJ does not maintain the original genetic 
information because the break ends can be processed allowing the formation of appropriate 
substrates which, after, can be directly connected (Dudáš and Chovanec, 2004; Ohnishi et al., 
2009).  
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1.5. Clinical chemotherapeutic agents – Temozolomide (TMZ) and Carmustine 
(BCNU) 
As mentioned previously, due to their capacity to induce several damages to DNA some 
alkylating agents are frequently used in cancer therapy. Nonetheless, response and toxicity of 
these agents is strongly modulated not only by DNA repair pathways but also by the genetic 
variability present in several cancers.   
BCNU, a chloroethylating agent, is an adjuvant agent very important in treatment of 
several cancers including brain tumors, lymphomas and melanomas. BCNU causes cytotoxic 
effects due to alkylation of O6 position of guanine (O6-chloroethylguanine - O6-ClethG). This 
monoadduct is converted through to internal cyclization into N1-O6-ethanoguanine (N1-O6-
ethanoG) that is capable to react with cytosine present in the complementary strand (N3-
cytosine) leading to the formation of N1-guanine-N3-cytosine interstrand crosslinks (ICLs) (Cui et 
al., 2009; Verbeek et al., 2008). BCNU also induces other types of DNA lesions such as 
monoadducts derived of alkylation in N1 and N7 positions of guanine (that do not lead to ICLs) 
(Cui et al., 2009). DNA damages created by this agent involve complex repair pathways. The O6-
ClethG are initially repaired by MGMT. Otherwise, the nucleotide excision repair, Fanconi anemia 
(FA) repair and homologous recombination (HR) are examples of downstream mechanisms 
required for complete depletion  of interstrand crosslinks. Due to their role on repair of the DNA 
lesions responsible to induction of cell death, the DNA repair pathways contribute to cancer cell 
resistance to BCNU (Drabløs et al., 2004; Kondo et al., 2010b; Verbeek et al., 2008). 
Temozolomide (TMZ), another DNA alkylating anticancer agent, is frequently used to treat 
brain tumors including glioblastoma multiforme, gliomas and anaplastic astrocytomas as well as 
melanomas. The small molecular weight and lipophilic proprieties of TMZ are the main 
characteristics which makes this agent highly efficient in these types of cancers (Koukourakis et 
al., 2009). Recently, TMZ has been applied in patients with metastatic colorectal cancer and a 
partial tumor regression was observed (Shacham-Shmueli et al., 2011).  
This agent does not require hepatic metabolism for its activation and is rapidly absorbed 
after oral administration. TMZ is a triazene compound that hydrolyses spontaneously 
transforming in the active metabolite MITC [5-(3-dimethyl-1-triazen-1-yl) imidazole-4-
carboxamide]. MTIC rapidly reacts and release carbonium ions that specially alkylate DNA at N7 
position of guanine (N7meG – about 70%), as well as N3 position of adenine (N3meA – about 9%) 
and O6 residues of guanine (O6meG – about 6%) (Zhang et al., 2012).  
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Just as in the case of BCNU, the primary DNA lesion O6-methylguanine (O6-meG) induced 
by TMZ is also eliminated by the DNA repair protein MGMT. However, the toxicity of TMZ is also 
dependent on the mismatch repair system that acts after the first cell cycle of replication. This 
DNA repair mechanism is important for this class of compounds because promotes the 
generation of DSBs that trigger cell death by apoptosis (Quiros et al., 2010). For successful 
repair of N-alkylations, caused by TMZ, the activation of functional BER system is also necessary 
(Liu and Gerson, 2006).  
Therefore, when applied alkylating agents, it becomes important an introduction of routine 
genetic analysis of patients tumors in order to develop individualized treatments which will allow 
better prognosis. 
1.6. Natural compounds and chemoprevention 
Due to the frequent exposure to environmental oxidanting and alkylating compounds, the 
diet and lifestyle have a great impact at the level of prevention of DNA damage and as a 
consequence of many diseases, such as cancer. Through epidemiological studies it has been 
possible to establish that a diet abundant in plant foods and some phytochemical components 
helps in the prevention of numerous cancers (chemoprevention), for instance, CRC (Liu, 2004; 
Pan et al., 2008; Ramos et al., 2008). Studies revealed the role of phytochemicals (mostly found 
in vegetables and fruits) in CRC. For example, quercetin, ursolic acid and luteolin showed to have 
anti-proliferative and pro-apoptotic effects in cell lines derived from CRC (Xavier et al., 2009). 
Thus, there is a growing interest in trying to isolate and identify specific compounds existent in 
the diet that may have effects on DNA protection and induction of DNA repair pathways. Overall, 
chemoprevention can be defined as a process in which natural or synthetic compounds are used 
to delay, reverse or prevent the growth tumor and may control its behavior through modulation of 
metabolic mechanisms and signaling pathways (Pan et al., 2008). 
Phytochemicals are an example of bioactive compounds present in plants that can act as 
antioxidant by neutralizing free radicals and oxidants, can induce iron chelation, promote the 
stimulation of cellular defense systems, and regulate the gene expression in cell proliferation, cell 
differentiation. They can also induce cell-cycle arrest or apoptosis. Phytochemicals can be divided 
into: carotenoids, alkaloids, polyphenols, nitrogen-containing compounds and organosulfur 
compounds. Polyphenols can be sub-divided into 4 groups, according to the amount of phenol 
rings: flavonoids, lignans, stilbenes and phenolic acids. On the other hand, flavonoids also can be 
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classified into 6 subgroups: flavonols, flavones, isoflavones, flavanones, anthocyanidins and 
flavanols (Liu, 2004). 
The most common dietary polyphenols are the flavonoids, like luteolin, rutin, quercetin, 
curcumin and resveratrol, and phenolic acids, including rosmarinic acid. Flavonoids have the 
ability to act as metal chelators and as free radical scavengers. These compounds may inhibit not 
only molecules involved in the inflammatory processes that culminate in transformation, 
proliferation and initiation of carcinogenesis but also may suppress the final steps of 
carcinogenesis namely metastasis and angiogenesis (Aggarwal and Shishodia, 2006). For 
instance, resveratrol and curcumin (present in grapes and turmeric, respectively) have the ability 
to downregulate the expression of apoptosis suppressor proteins Bcl-2 and NF-kB, and increase 
caspases activity and Bax levels. Quercetin (which is found in citrus fruit and apples) for example 
upregulate proteins involved in apoptosis such as Bax and caspases but also proteins that 
intervene in cell death and DNA repair.  
MGMT, as previously mentioned, has an important role in cancer prevention of normal 
cells against exogenous and endogenous carcinogens promoting the removal of initial O6-alkyl 
adducts from DNA template. This protein is the first line of defense when are formed alkylating 
damage in DNA. Thus, it becomes highly desirable, in terms of chemoprevention, that natural 
compounds have the ability to enhance the expression of MGMT. Studies have reported that 
curcumin, resveratrol and silymarin enhance MGMT expression levels in cancer cell lines (Niture 
et al., 2006a). Another study showed that some medicinal plants extracts, such as holy basil 
(Ocimum sanctum), oregano (Origanum majorana) and winter cherry (Withania somnifera) 
increased protein expression of MGMT. Although to a smaller extent, plant extracts derived from 
gooseberry (Emblica officinalis) or spearmint (Mentha viridis) also promote the increase of MGMT 
levels (Niture et al., 2006b). In addition, as tumor cells exhibit several methylated genes, some 
constituents of the diet such as (2)-epigallocatechin 3-gallate (EGCG) and genistein have been 
demonstrated to have the ability to reactivate the MGMT gene epigenetically silenced. This effect 
is associated with the inhibition of DNA methyltransferases (DNMT) that results in the 
demethylation of GpC islands in the MGMT promoter (Fang et al., 2007). These results show a 
beneficial effect for cancer prevention because would provide the removal of alkylating damages 
introduced in DNA but, on the other hand, may decrease the effectiveness of cancer therapy 
since this protein would remove DNA damages if cancer patients are treated with alkylating 
chemotherapeutic agents. Chemopreventive agents have been demonstrated that may help 
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improve the efficiency of cancer patients, when applied concomitantly with chemotherapy (Sarkar 
and Li, 2006). However, diet may also be used to improve the effects of chemotherapy with 
alkylating agents and, therefore, compounds that decrease MGMT activity or increase MMR 
repair should be chosen.  
1.7. p53 – the tumor suppressor 
The tumor suppressor p53 is encoded by the TP53 gene and has a relevant role in cancer 
being referred to as the “guardian of the genome” due to the many functions it exercises to 
maintain cell homeostasis. It is recognized as a transcription factor involved in the regulation of 
many genes being usually present at low levels in normal cells. This protein is negatively 
regulated by MDM2, an E3 ubiquitin ligase, which targets p53 for ubiquitination allowing its 
elimination by the proteasome. p53 is activated in response to some stresses such as DNA 
damage (radiation, UV, chemotherapeutic drugs), hypoxia, heat shock and oncogene activation 
(Chari et al., 2009). In response to these stimuli, post-translational modifications occur in this 
molecule that will promote its translocation to the nucleus and binding to specific DNA sequences 
that are present in the promoters of target genes. Activation of p53 leads to improved DNA 
repair, cell-cycle arrest, stimulation of cell death by apoptosis or senescence (Chari et al., 2009). 
The induction of apoptosis by p53 occurs by direct interaction with components involved in 
mitochondrial pathway of apoptosis through to the inhibition of anti-apoptotic proteins (namely, 
Bcl-2 and Bcl-x) and activation of pro-apoptotic family proteins (including BAX, PUMA, FAS 
receptor, APAF-1 but also FasR) (Kaina et al., 2007; Vaseva and Moll, 2009). In response to DNA 
damage, there is the activation of some DDR proteins, namely ATM and ATR. CHK1 and CHK2, 
the targets of ATR and ATM respectively, phosphorylate p53 which reduces the degradation of 
p53 by MDM2. Activation of p53 induces for instance in the case of DNA repair GADD45α, XPC, 
OGG1 and DNA polymerase (Sengupta and Harris, 2005). 
One of the main reasons for p53 to be one the most studied proteins is that about 50% of 
all cancers, including colorectal, have inactivating mutations of p53 (Lu and El-Deiry, 2009). It 
has been widely reported that tumors that retain a wild-type p53 gene sequence have better 
sensitivity to chemotherapy and radiotherapy (Chari et al., 2009). For instance in ovarian cancer 
patients, an association between resistance to cisplatin treatment and expression of mutant p53 
gene was found (Shelling, 1997).  Also, colorectal and gastric cancers that contain mutations in 
p53 sequence were less chemosensitive (Hamada et al., 1996). In contrast to previous data, a 
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recent study demonstrated that melanoma cell lines with WTp53 were more tolerant to TMZ 
when compared with p53 mutant lines deficient in the MMR system (Naumann et al., 2009). 
Also, Blough and collaborators described that glioma cell lines without p53 are more susceptible 
to TMZ than cells with functionally wt p53 expression (Blough et al., 2011).  
Therefore, more experiments are needed to clarify the interaction between the therapeutic agents 
and p53 protein in order to improve treatment. In particular it is necessary to clarify the 
involvement of p53 with regard to the use of alkylating agents. 
1.8. Apoptosis 
Apoptosis or programmed cell death is a fundamental cellular process of that plays a 
crucial role in cellular homeostasis (Qiao and Wong, 2009).  
During the apoptotic process several morphological modifications occur in cells including: 
plasma membrane blebbing, formation of apoptotic bodies and nuclear chromatin condensation. 
In the early phase, after plasma membrane blebbing a “budding” process occur that consists in 
division of cell fragments into apoptotic bodies (surrounded by intact plasma membrane).  
Apoptosis can be divided in two important pathways: the intrinsic pathway (also identified 
as the mitochondrial pathway) and extrinsic pathway (also designated as the death receptor 
pathway). The two pathways differ in some aspects. The intrinsic pathway is activated by several 
cellular stresses including DNA damage, ionizing radiation, hypoxia and ROS. Briefly, the cellular 
injury promotes the permeabilization of the outer mitochondrial membrane leading to the release 
of cytochrome c for cytoplasm. The cytochrome c binds to the Apaf-1 (apoptotic protease-
activating factor-1) causing the activation of procaspase 9 creating the apoptosome. This complex 
then activates effector caspases including caspase 3 and 6. On the other hand, the extrinsic 
pathway is activated through ligand binding of death receptors (located in the plasma 
membrane). Tumor necrosis factor-α (TNF-α) and Fas-L are examples of death ligands and, its 
binding to the receptor promote the recruitment of death signal adaptor proteins (such as Fas-
associated death domain (FADD)) and activation of procaspases 8 or 10. In turn, these 
procaspases activate effector caspases such as 3 and 9. Despite of the differences described 
above, it is possible noted that a crosslink exists between the two pathways (Qiao and Wong, 
2009).  
Defects in this cellular process confer cells a survival advantage leading to the malignant 
transformation. Therefore, deregulation of apoptotic pathways have been frequently linked to 
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cancer initiation, progression as well as resistance to chemotherapy also in CRC. Cancer 
therapies are often based on induction of apoptosis in cancer cells and it has been amply 
recognized as a good therapeutic strategy for several cancers. In CRC, some alterations in the 
expression of proteins involved in apoptotic process have been described lead to 
chemoresistance. For instance, changes in caspase activation (which are cysteine proteases) 
including mutations in caspase 3, caspase 8 have been described. Frequently, alteration in 
expression levels of Bcl-2 family members, e.g. high expression of anti-apoptotic proteins (such 
as Bcl-2 and Bcl-X) and low levels of pro-apoptotic proteins (for example, Bax and Bak) have been 
established in CRC (Hector and Prehn, 2009).  
A major inducer of cell death by apoptosis is DNA damage. Alkylating agents, such as 
BCNU and TMZ, are some examples of compounds that exert their cytotoxicity based on the 
induction of the DNA damage and induction of DDR, leading to cell cycle arrest and apoptosis. 
Apoptosis induced by these compounds is the consequence of blockage of the replication 
process by stalled replication forks and formation of DSBs. DSBs are detected by DDR signaling 
which signal downstream factors such as CHK1, CHK2 and p53. The transcriptional activation of 
pro-apoptotic proteins (including Bax and FasR) occurs. Several studies have shown that 
apoptosis caused by chemotherapeutic agents is due to induction of DNA damages. Methylating 
agents capable of inducing O6meG lesions trigger apoptosis by the combined action of MGMT and 
MMR systems. If this lesion remains in the template, after two cycles of replication, leads to 
DSBs formation and induction both apoptotic pathways. On the other hand, the processing of N-
alkylations may also trigger apoptosis if repair by BER system is deficient and these lesions can 
create AP sites and SSBs that induce blockage of DNA replication process resulting in DSBs 
(Roos and Kaina, 2013). In the case of chloroethylating agents, the induction of crosslinks are 
the mainly lesions that promote the blockage of replication and collapse of replication forks and 
consequently may trigger both apoptotic pathways (Roos and Kaina, 2006). 
In this project the recently developed CoMeth assay will be used to confirm its applicability 
to the study of chemotherapeutic drugs (TMZ and BCNU) and the characterization of the 
involvement of MGMT, MMR and p53 in DNA damage produced and cell death induction. 
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Alkylating agents are used in chemotherapeutic strategies due to their ability to induce 
DNA damage. These lesions can trigger cell cycle arrest and cell death. However, the use of 
alkylating anticancer agents is limited by resistance mainly due to mechanisms of DNA repair. 
MGMT and MMR are important players, and for instance, active MGMT and downregulation of 
MMR system benefits the cancer cells decreasing the induction cell death and, consequently, the 
responsiveness to alkylating anticancer agents. In other perspective, a normal function of DNA 
repair systems has a relevant role in the prevention of mutations that lead to carcinogenic 
process.  
The comet assay is amply used for measure, for instance, oxidative DNA damages and 
evaluation of cellular effects induced by natural compounds. A simple reliable methodology to 
evaluate methylating DNA damage by the comet assay has been recently developed in our 
laboratory (CoMeth) using MGMT-inhibited and MMR-proficient cells. This tool allows explore the 
role of MGMT and MMR system in the response to alkylating agents. 
 
In this context, the aims of this work are: 
- Demonstrate the applicability of the CoMeth assay to measure alkylating DNA 
damages induced by methylating (TMZ) and chloroethylating agents (BCNU), namely, 
O6meG and O6ClethG, respectively, under MGMT inhibition with O6-BG. 
 
- Evaluate the role of MMR system for the DNA effects induced by two alkylating agents, 
TMZ and BCNU, on induction of DNA damage and cell death in colorectal cancer cells. 
 
- Investigate how the expression of wt-p53 influences the sensitivity of colorectal cancer 
cells to alkylating drugs and the ability of the two alkylating agents to induce apoptosis.  
 
-  Evaluate the potential effects of some phytochemicals on expression levels of the 
repair enzyme MGMT. 
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3.1. Cell lines, culture conditions and reagents 
Caco-2 cell line (extracted from a human epithelial colorectal adenocarcinoma) is DNA 
MMR-proficient but harbors a G/A (Arg/His) mutation in codon 273 of the p53 gene (Liu and 
Bodmer, 2006). This cell line was cultured as a monolayer culture in Dulbecco’s modified 
Eagle’s medium (DMEM)(Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Biochrom KG, Berlin, Germany) and 1% (v/v) antibiotics (100 U/mL 
penicillin and 100 µg/mL streptomycin)(Sigma-Aldrich, St. Louis, MO, USA). 
HCT116 cell lines (derived from human colorectal carcinoma), p53-wild-type and p53 
complete knockout for p53 cells (provided by Vogelstein) (Bunz et al., 1998). These cell lines 
contain homozygous mutation in hMLH1 resulting in a nonfunctional protein, and consequently, 
in deficient DNA mismatch repair (MSI)  (Table 3.1) (Goel et al., 2006). The cell lines were grown 
in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) and supplemented with 6% FBS (v/v), 
1% (v/v) antibiotic/antimycotic solution and 0.1 mM pyruvate (Sigma-Aldrich, St. Louis, MO, 
USA). All cell lines were grown and maintained under an atmosphere containing 5% of carbon 
dioxide (CO2) at 37°C. Cellular subcultures were performed when confluence reached values 
close to 80- 90%. Cells (Caco-2 and HCT116) were maintained and grown in 75 cm2 and 25cm2 
tissue culture flasks (TPP) respectively. The medium was renewed 2 times per week. For 
subcultures and plating, the adherent cells were detached with trypsin solution 1% (Sigma-
Aldrich, St. Louis, MO, USA) and, fresh medium was added in order to neutralize the trypsin and 
a cell suspension was obtained. Then, this suspension was loaded in a hematocytometer and the 
concentration of cells present in the suspension was estimated by the following formula: mean of 
cells in the four quadrants x dilution factor x 104 = number of cells per ml.  
 
 
 Tumor suppressor p53 gene MMR system 
Caco-2 cells Mutated Wild-type 
HCT116 cells Wild-type Mutated 
 
 
Stock solutions of TMZ, BCNU and O6-BG were prepared in dimethyl sulfoxide (DMSO) and 
aliquots were kept at -20°C. The three compounds were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). The DMSO concentration that is placed in the culture medium in all conditions 
did not exceed 0.5% (v/v) and the controls were treated only with the vehicle (DMSO).  
Table 3.1 – Mutations presents in Caco-2 and HCT116 colorectal cancer cell lines. 
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Ursolic acid (UA), Quercetin (Q), Curcumin (Curc), Silibinin (Sil) Resveratrol (Resv), 
Oleanolic acid (OA) and Rutin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Luteolin 
(L) was from Extrasynthese (Genay, France) and Rosmarinic acid (RA) from Fluka (St. Louis, MO, 
USA). All of stock solutions were dissolved in DMSO and aliquots were kept protected for light at -
20°C.  
Depending on the experiments, cells were plated in 12- (MTT and comet assay) or 6- 
(Western blot or nuclear condensation assay) multiwell culture plates with 1 or 2ml/well 
respectively, at a density of 0.1 x 106 (in the case of Caco-2 cells) and 0.6 x 105 (for the two 
isogenic HCT116 cell lines) cells/ml. For assays with application of alkylating agents, forty-eight 
hours after plating, the medium was discarded and fresh medium containing O6-BG (100µM) was 
added 2h prior to alkylating treatment, for complete depletion of MGMT. Next, without changing 
the medium, the two alkylating agents, BCNU at 100µM and TMZ at 200µM, were added in 
order to promote DNA alkylating damage. As control, the cells were also incubated only with O6-
BG or DMSO (vehicle). On the other hand, for assays with natural compounds, forty-eight hours 
after plating, the medium is discarded and fresh medium with natural compounds were added. 
For each method, the cells were harvested after specific periods of incubation, as will be 
described in the following sections. 
3.2. Cell toxicity by MTT reduction assay 
The MTT reduction assay was performed in order to select concentrations that cause 
significant inhibition of cell viability and, simultaneously, that induce alkylating DNA damage. This 
assay allowed us to determine the chemosensitivity of Caco-2 and HCT116 cells to TMZ, BCNU, 
O6-BG, O6-BG plus TMZ and O6-BG plus BCNU treatments. 
This colorimetric assay involves the conversion of the water soluble MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in insoluble formazan, giving a purple 
color, allowing its spectrophotometric quantification. The bioconversion of MTT to formazan is 
performed by dehydrogenase enzymes found in metabolically active cells. This reduction involves 
the activity of intracellular oxidation-reduction systems, and consequently, the number of viable 
cells is directly proportional to the amount of formazan crystals produced (Sylvester, 2011). 
After 48, 72 and 96h, 100 µL of MTT (5mg/mL, diluted in phosphate-buffered saline 
(PBS) solution and maintained in the dark and at 4°C) (Sigma-Aldrich, St. Louis, MO, USA) was 
added to each well and cells were incubated at 37°C, with 5% CO2 during 1 hour, allowing the 
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formation of formazan crystals. Then, the medium was removed from the wells and 
DMSO/ethanol solution (proportion 1:1) was then used to dissolve the formazan crystals. When 
all crystals were entirely dissolved, from each well 200µL of solution were taken and platted onto 
96 wells and absorbance was measured with a microplate reader (SpectraMax Plus 384 Microplate 
Reader – Molecular Devices) at a wavelength of 570nm. As a blank, it was used only 200µL of 
DMSO/ethanol solution. The results were treated as a percentage of cell viability in relation to 
control (untreated cells, which was defined as 100% of cell viability). For that, the value 
correspondent to MTT reduction at the beginning of incubation (t = 0 h) was subtracted from all 
the experimental conditions, including the control. MTT negative values indicate cell death due to 
cytotoxicity while values between 0% and 100% indicate cell viability.  
 
3.3. Nuclear condensation 
In order to evaluate the effect of O6-BG, TMZ, BCNU, O6-BG plus TMZ and O6-BG plus BCNU 
treatment on induction of apoptosis in Caco-2 cells and in two isogenic HCT116 cell lines the 
nuclear condensation assay was performed. After incubation time (48, 72 and 96h), the medium 
was collected to harvest dead cells and the attached cells were treated with trypsin solution 
during 5min. Trypsin was then neutralized with the respective harvest medium and collected to 
respective falcons that were then centrifuged at 2000rpm’s to 10min and the pellet was 
ressuspended in 500μL of medium. Then, the cells were fixed with 4% paraformaldehyde (PFA) 
for approximately 20 minutes at room temperature and after this time they were washed once 
with PBS and centrifuged in the same conditions referred above. Finally, the solution inside the 
falcon was aspirated up to 500µL, the pellet was ressuspended in this solution and harvest to 
eppendorfs. Posteriorly, the cells were attached onto a polylysine-treated slide using a Shandon 
Cytospin at 500rpm for 5min. In the second step, polylysine slides were washed two times with 
PBS during 5min.  In order to visualize apoptotic cells in the different conditions tested, the cells 
were stained with 20μL of Hoechst, which stains nuclear DNA, for 10min in the dark chamber. 
The dye was kept at 4oC in aliquots of 0.5 mg/mL (Sigma-Aldrich, St. Louis, MO, USA).  This dye 
was diluted in PBS (1:100) so the final concentration was 5μg/mL. After this incubation time, 
6μL of glycerol 50% was added in order to fix the coverslip to the slide. Under an inverted 
microscope equipped with a fluorescent light source (DAPI fluorescence filter) (Olympus IX71), 
the number of cells in each condition was determined. The percentage of apoptotic cells was 
3. Material and Methods 
 36  
 
calculated from the ratio between cells that exhibit nuclear condensation and total number of 
cells. For each condition, more than 500 cells were counted (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
3.4. DNA damage assessment by comet assay 
In the present work we chose to evaluate the DNA damage induced by alkylating agents 
TMZ and BCNU under MGMT inhibition with O6-BG through to the alkaline version of the single-
cell gel electrophoresis assay (also known as CoMeth assay) as previously described (Collins, 
2004).  
The alkaline version is frequently recommended since it detects DNA damage, including 
SSBs, DSBs and alkali-labile sites (ALS) (Speit et al., 2004). This method for quantification of 
DNA damages has some advantages, such as: simple and fast; inexpensive; easy to execute in 
any tissue; allows the detection of multiple DNA damage (as referred above); allows evaluation of 
DNA lesions in individual cell; may be used in cases of low levels of DNA damage due to a high 
sensitivity; only requires a small quantity of cells per sample and can be applied in proliferative or 
non-proliferative cells (Hartmann et al., 2003).  
To perform the comet assay, after 1, 48 and 72h of incubation of Caco-2 and HCT116 
cells with BCNU (100µM) and TMZ (200µM), with or without O6-BG (100µM), cells were washed 
in PBS solution, trypsinized and ressuspended in fresh medium. From each well was removed, to 
respective eppendorf, the volume required to obtain approximately 2 x 104 cells. This volume was 
centrifuged (at 0.6 rpm for 2min) and the resulting pellet was ressuspended in low melting point 
Figure 3.1 – Assessment of nuclear condensation and apoptotic bodies by Hoechst staining in Caco-2 cells 
exposed to BCNU treatment after 72h of incubation. Amplification 400 x. White arrow indicates cells with 
nuclear condensation. 
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agarose (LMP, 0.5%). The mix was then placed on a slide, which was pre-coated with normal 
melting point agarose (NMP, 1%). After 10min at 4°C in order to solidify the agarose, the slides 
were placed in lysis solution (Annexes) during at least 1h at 4°C. This solution breaks the 
membranes and removes cellular contents, essentially histones, leading to the appearance of 
nucleoids of supercoiled DNA. After lysis, the slides were immersed in electrophoresis buffer 
(Annexes) at 4°C during 40 minutes under alkaline conditions (pH > 13) with the aim to occur 
DNA unwinding. Then, the slides were submitted to electrophoresis during 20min at 4°C, 21 V 
(0.8 V/cm) and 300mA. So, in this step the DNA that contains breaks migrates toward the anode 
leading to formation of the structures resembling a comet, with a head (that contains the intact 
DNA) and a tail (DNA loops that contains breaks). Afterwards, the slides are washed with water 
and dehydrated with absolute ethanol during 5min. Each sample was stained with specific 
nucleic acid fluorescent die (SYBRGold) during 30min at 4°C. After drying the slides were 
visualized on a fluorescence microscope (Leica, DM5000b + CTR5000 + ebq100) equipped with 
GFP filter. SYBR Gold was purchased from Invitrogen Molecular probes (Oregon, USA) and the 
aliquots were diluted in PBS 1X and maintained at 4°C (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 Figure 3.2 – Representative scheme of general steps involved in standard comet assay (Adapted from (Ramos et 
al., 2011)). 
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For definition and using the Comet IV analysis system (Perceptive Instruments Ltd, 
Haverhill, UK), approximately 100 cells are analysed per sample. Through this program it was 
possible to calculate the percentage of DNA in tail. Thereby, for every single cell this program 
measure intensity of fluorescence in the comet tail and head and attributes a percentage of DNA 
present in tail.  
 
3.5. Protein extraction and Western Blot analysis 
The effect of incubation with natural compounds (UA, Q, Curc, Sil, Resv, OA, R, L, RA) on 
MGMT protein expression, involved in the DNA repair of alkylating damage, was evaluated by 
Western blot after 48h.  
After 48h of incubation, the cells were washed with phosphate-buffered saline (PBS) 
solution, trypsinized and medium was added for neutralizing the trypsin. The medium of each 
condition was collected to the respective falcon, the samples were centrifuged at 2000 rpm for 
10min at 4°C. The cells were ressuspended in respective medium and harvest to individual 
eppendorfs. The cells were then lysed using ice-cold RIPA buffer (1% NP-40 in 150mM NaCl, 
50mM Tris-HCl (pH 7.5), 2mM EDTA) supplemented with 20mM of sodium fluoride (NaF), 1mM 
phenylmethylsulfonyl fluoride (PMSF), 20 mM of Sodium orthovanadate (Na3VO4), and protease 
inhibitor cocktail (Roche, Mannheim, Germany) and samples centrifugated at 10 000 g (4º C) for 
10 min. The soluble protein concentration was determined using Bio-Rad DC protein assay (Bio-
Rad Laboratories, Inc., Hercules, CA, USA). The protein concentration of each sample was 
determined using a calibration curve with a standard protein solution, a bovine serum albumin 
(BSA). Posteriorly, for each condition 20μg of protein was separated through to 12% sodium 
dodecyl sulphate (SDS)-polyacrylamide gel. Protein band was transferred to Hybond-P 
polyvinylidene difluoride (PVDF) membranes (GE Healthcare). The membranes were blocked in 
PBS with 0.05% Tween-20 (TPBS) with 5% (w/v) non-fat dry milk, at least 2 h at room 
temperature and washed three times in TPBS solution.  The membranes were then incubated 
overnight (4°C) with primary antibody (Table 3.2). Membranes were placed in secondary 
antibody (containing IgG horseradish peroxidase) during 1 h at room temperature, following three 
TPBS washes. Immunoreactive bands were detected through Immobilon solutions (Millipore, 
Billerica, MA, USA) and acquired using the chemiluminescence detection system (Chemi Doc 
XRS; Bio-Rad Laboratories, Inc.). As loading control Β-actin antibody was used. The Quantity One 
software was used to quantify the area intensity of the bands. The results were expressed as 
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relative percentage of control (β-actin). Control condition was considered to correspond to 100% 
of expression. 
 
 
Primary Antibody Dilution Secundary antibody Source 
MGMT 1:500 Mouse 
Santa Cruz 
Biotechnology (Santa 
Cruz, CA, USA) 
MLH1 1:1000 Rabbit 
Santa Cruz 
Biotechnology (Santa 
Cruz, CA, USA) 
MPG 1:2000 Mouse 
Abcam (Cambridge, UK) 
APE-1 1:2000 Mouse 
Abcam (Cambridge, UK) 
β-actin 1:2000 Mouse 
Sigma-Aldrich, St. Louis, 
MO, USA 
 
3.6. Statistical analysis 
All experiments were performed at least three times and treated as means ± SEM. The 
results were evaluated statistically using the Student’s t-test. Statistically significant differences 
between cells with or without pre-incubation with O6-BG were considered when p-values ≤0.05 (* 
p ≤ 0.05; ** p ≤ 0.01;***p ≤ 0.001). The One-way ANOVA test followed by Tukey’s Multiple 
comparison test was used to analyse differences in percentage of DNA damage as function of the 
time after treatment with or without O6-BG pre-incubation. Significant differences were considered 
when p-values ≤0.05 (# p ≤ 0.05; ## p ≤ 0.01; ### p ≤ 0.001). All the statistical analyses were 
performed through to the GraphPad Prism 5.0 software (San Diego, CA, USA). 
 
 
 
 
 
 
 
Table 3.2 – Antibodies and respective secondary antibodies used in western blot assay. 
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4.1 Effects of TMZ, BCNU and O6-BG on cell viability 
In order to define an adequate concentration of TMZ and BCNU agents, that are able to 
induce 50% of toxicity and cause DNA damages on Caco-2 cell line, a MTT assay was performed 
using several concentrations of the two alkylating agents in study (range between 1µM - 200µM) 
(Annexes). This experiment allowed us to choose the concentration of 200 µM to TMZ and 
100µM to BCNU. So, for all experiments of this work were used the concentrations mentioned 
above. In order to evaluate the effect of pre-incubation with or without O6-BG followed TMZ or 
BCNU treatment on cellular viability the MTT assay was performed (Figure 4.1-A and B). The 
defined time of incubation and the concentration of O6-BG that significantly inhibited the MGMT, 
100µM during 2h, have been defined in previous studies (Ramos et al., 2013). 
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Figure 4.1 – Effect on cellular viability of (A) TMZ (200µM), O6-BG (100µM), and O6-BG plus TMZ (B) and BCNU 
(100µM), O6-BG (100µM), and O6-BG plus BCNU treatment on Caco-2 cell line, by MTT assay. The cells were pre-
incubated during 2h with or without O6-BG (100µM) before TMZ (200µM) or BCNU (100µM) treatment for 48, 72 
and 96h. The percentage of cell viability was calculated by the absorbance relative to the value detected for the 
control cells (untreated cells), that was defined as 100% of cell viability. For each condition were performed three 
independent experiments and data are expressed as mean ± SEM. Significant differences were found, by Student’s 
t-test, when compared with respective control (* P<0.05; ** P < 0.01; *** P < 0.001). Through One-way ANOVA 
significant differences over time of incubation (# P<0.05) were found.  
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The results showed that (Figure 4.1 - A), when the cells were pre-incubated with the MGMT 
inhibitor, O6-BG, followed by exposure of TMZ, there is a more pronounced decrease of viable 
cells compared to untreated cells. It was also observed that cells only treated with methylating 
agent TMZ exhibited a decrease of number of viable cells when compared with the respective 
control with reached values close to 50% of cell viability. Significant differences in cell viability 
were found after 72h of TMZ treatment with or without pre-incubation with O6-BG. Relatively to 
BCNU treatment it was verified that cells treated with O6-BG or BCNU for 48, 72 and 96h showed 
a significant decrease of cell viability when compared with the respective control (Figure 4.1 – B). 
The pre-incubation with O6-BG followed by BCNU treatment decreased cell viability more 
drastically compared than the isolated drugs, mainly after 72 and 96h. At 96h, negative values 
were obtained in cells with O6-BG plus BCNU treatment and this indicates that the induction of 
cell death occurred.  
Therefore, for both alkylating drugs, a significantly higher inhibition of cell viability was 
observed in the presence of the MGMT inhibitor – O6-BG potentiating BCNU and TMZ cytotoxicity. 
 
4.2. Genotoxic effects of TMZ, BCNU and O6-BG in Caco-2 cell line 
 
 We initially hypothesized that the comet assay could be applied to evaluate the levels of 
O6-meG and O6-ClethG lesions in DNA induced by TMZ and BCNU, respectively, in Caco-2 cells a 
MMR-proficient cell line. To test this hypothesis, Caco-2 cells were used and O6-BG was used as 
an inhibitor of MGMT. This cells were subjected to treatment with TMZ (200µM) or BCNU 
(100µM) in the presence or absence of the MGMT inhibitor – O6-BG (100 µM) at different 
incubation times (1, 48 and 72h). The parameter “percentage of DNA in tail” was used to 
evaluate the DNA damage induced (Collins and Azqueta, 2012). 
After 1h of incubation with TMZ, an increase in DNA damage was observed with or without 
O6-BG when compared with control cells (only DMSO) (Figure 4.2 - A). 
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It is also possible to observe that when Caco-2 cells were pre-incubated with O6-BG 
followed TMZ treatment DNA damages remained high over time. However, the same pattern 
cannot be seen for cells treated only with TMZ because DNA damage decreased significantly over 
time. After 72h, a significant difference in DNA damage between cells without or with O6-BG pre-
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Figure 4.2 - Effect on DNA damage induced by (A) TMZ and (B) BCNU in the absence or presence of O6-BG, 
evaluated by the comet assay, on Caco-2 cells. The cells were pre-incubated, during 2 hours, with or without O6-BG 
(100µM) before TMZ (200µM) or BCNU (100µM) treatment for 1, 48 and 72h. For each condition were performed 
three independent experiments and data are expressed as mean ± SEM.  Significant differences (*P < 0.05), 
determined by Student t-test, were found between cells with and without pre-treatment with O6-BG at 72h. One-way 
ANOVA (followed by Tukey’s Multiple comparison test) showed statistically significant differences over time between 
cells with or without pre-treatment with O6-BG (# P<0.05; ## P<0.01; ### P< 0.001), when compared with 1h of 
treatment with or without O6-BG, respectively. 
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treatment was detected. In both untreated cells and cells incubated with O6-BG alone the DNA 
damages remained low during the complete experiment.  
The chloroethylating agent, BCNU, seemed to have a similar effect to TMZ on Caco-2 cell 
line. As demonstrated in Figure 4.2 - B, after 1h of BCNU incubation, it was observed that BCNU 
significantly induced DNA damages with or without O6-BG pre-incubation. During all time of the 
experiment, in the presence of O6-BG, the DNA damage remained significantly high. On the other 
hand, over time a progressive and significant decrease in DNA damages was observed when cells 
were incubated with the alkylating agent only and a significant difference was found compared 
with cells pre-treated with O6-BG after 72h of incubation. As expected, the results did not show 
any effects on DNA damages either in untreated cells (control cells) or in cells pre-treated with O6-
BG only.  
Taken together, our results show a strong indication that O6meG and O6ClethG may be 
detected simply and quickly through the use of comet assay and, that, the presence of O6-BG 
increased the genotoxicity of the chemotherapeutic drugs. 
 
4.3. Effects of TMZ, BCNU and O6-BG on cell death in Caco-2 cells 
 
As mentioned above, both methylating and chloroethylating agents induced a progressive 
increase in DNA damage when cells were previously incubated with the inhibitor of MGMT 
protein, O6-BG. Taken these results into account it was decided to explore if this DNA damage 
triggered cell death by apoptosis, as detected by the nuclear condensation assay. 
The results obtained showed that Caco-2 cells pre-treated with the O6-BG followed by TMZ 
treatment, showed a significant increase in the percentage of apoptotic cells at 96h of incubation. 
This result is in agreement with the results obtained for DNA damage at 72h, when cells were 
also pre-treated with O6-BG before TMZ treatment. On the other hand, Caco-2 cells treated either 
with TMZ (200µM) or O6-BG (100µM) alone did not show a significant enhancement in the 
number of apoptotic cells during entire time of the experiment (Figure 4.3 – A). As expected, 
control cells did not display any changes on the percentage of apoptotic cells over time of 
experiment. 
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A similar behaviour was observed when cells were incubated with BCNU or O6-BG agents 
alone since an increase in the percentage of apoptotic cells during 96h of treatment did not 
occur (Figure 4.3 – B). When cells were pre-incubated with O6-BG followed with BCNU treatment, 
it was possible detect early (only after 72h) a statistical significant differences in percentage of 
(A) 
(B) 
Figure 4.3 – Effect on induction of apoptosis, in Caco-2 cells, after incubation with (A) TMZ (200µM), O6-BG (100 
µM) or O6-BG plus TMZ and with (B) BCNU (100µM), O6-BG (100 µM) or O6-BG plus BCNU. Apoptosis was evaluated 
through nuclear condensation assay after 48, 72 and 96h of treatment. The percentage of apoptotic cells were 
calculated through to the ratio between cells in nuclear condensation and the total number of cells. For each 
condition were performed three independent experiments and data are expressed as mean ± SEM. Significant 
differences were found, by One-way ANOVA followed by Dunnett’s Multiple comparison test, when compared with 
respective control (untreated cells) (** P < 0.01; *** P < 0.001). 
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apoptotic cells compared with respective control, since a pronounced increase occurred in this 
condition (about 5%). Over time control cells did not show any significant change in percentage of 
apoptosis.   
 
4.4. Role of DNA mismatch repair on induction of DNA damages and apoptosis by 
alkylating agents 
 
In this part of work, we try characterize the contribution of MMR DNA repair system for the 
recognition of O6meG and O6ClethG, initial lesions caused by TMZ and BCNU respectively, and 
formation of DNA strand breaks. For that, we used a colon cell line HCT116 that contains a 
mutation in hMLH1 and consequently has a defective MMR system (Goel et al., 2006). 
Comparison with the results obtained with the MMR proficient Caco-2 cells will demonstrate the 
MMR dependence. 
As shown in Figure 4.4 - A, after 1h of incubation with TMZ only or O6-BG plus TMZ 
treatment significant DNA damages were detected by comet assay in HCT116 cells. However, at 
72h for both situations (TMZ and O6-BG plus TMZ), a significant reduction in percentage of DNA 
in tail occurred, i.e., the damages were almost entirely repaired. It is verified that at 72h, the 
amount of DNA damages was equivalent to the control values. Non-significant differences were 
found between cells with or without O6-BG treatment followed by TMZ agent incubation.  
The results demonstrate that, MMR deficient cells, even when the O6meG lesions are not 
repaired due to MGMT inhibition, do not have the capacity to detect the alkylating DNA damage 
and promote strand breaks formation. In MMR-deficient cells, MGMT inhibition is not sufficient to 
cause SBs in DNA after methylating agent treatment.  
As shown in Figure 4.4 – B, the DNA lesions induced by BCNU after 1h of incubation were 
elevated independently of whether the cells were pre-incubated with O6-BG or not. It can be seen 
that, when MMR-deficient cells were pre-incubated with O6-BG and then treated with BCNU the 
DNA damage (strand breaks) remained significantly high for 72h. On the other hand, the effects 
of BCNU treatment, without O6-BG, on DNA damage decreased significantly over time. 
Consequently, at 48h cells exhibited significantly higher levels of DNA damages comparatively 
with cells without MGMT inhibitor.  Over time of incubation, both untreated cells and cells 
incubated only with O6-BG did not show significant variations in percentage of DNA damage.  
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Afterwards, to assess whether the O6meG and O6ClethG lesions that are converted during 
replication into SBs (that are detected by the comet assay) trigger apoptotic cell death we 
performed the nuclear condensation assay. 
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Figure 4.4 - Effect on DNA damage induced by (A) TMZ and (B) BCNU in the presence or absence of O6-BG 
evaluated by the comet assay on HCT116 p53-wt cell line. The cells were pre-incubated, during 2 hours, with or 
without O6-BG (100µM) before TMZ (200µM) or BCNU (100µM) treatment for 1, 48 and 72h. For each condition 
were performed three independent experiments and data are expressed as mean ± SEM.  Significant differences 
(*P < 0.05; ** P < 0.01), determined by Student t-test, were found between cells with and without pre-treatment 
with O6-BG at 48h and 72h. One-way ANOVA followed by Tukey’s Multiple comparison test, showed statistically 
significant differences over time between cells without pre-treatment with O6-BG (## P<0.01; ### P< 0.001), 
when compared with 1h of treatment.  
(A) 
(B) 
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As expected, the results obtained for cell death are in agreement with those described for 
comet assay in case of persistent DNA breaks. Therefore, neither O6-BG (100µM) nor TMZ 
(200µM) alone or in combination caused a significant enhanced of the percentage of apoptotic 
cells in this defective MMR cell line over the time (Figure 4.5 – A). Taken together, our results of 
TMZ demonstrated that the presence of functional MMR system is required for recognition and 
removal of the lesions leading to formation of breaks in DNA (that are detected by comet assay) 
that trigger cell death by apoptosis. 
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Figure 4.5 – Effect on induction of apoptosis, in HCT116 p53-wt cell line, after incubation with (A) TMZ 
(200µM), O6-BG (100 µM) or O6-BG plus TMZ and with (B) BCNU (100µM), O6-BG (100 µM) or O6-BG plus BCNU. 
Apoptosis was evaluated through nuclear condensation assay after 48, 72 and 96h of treatment. For each 
condition were performed three independent experiments and data are expressed as mean ± SEM. Significant 
differences were found, by One-way ANOVA followed by Dunnett’s Multiple comparison test, when compared with 
respective control (untreated cells) (* P<0.05; ** P < 0.01). 
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Conversely, in the case of BCNU treatment it was observed that, BCNU only as well as O6-
BG plus BCNU induced a significant increase of apoptosis compared with respective control cells 
(Figure 4.5 – B). However, more pronounced levels of apoptotic cell death were obtained only in 
the presence of MGMT inhibitor. Control cells and cells only incubated with O6-BG did not show a 
significant variation in percentage of apoptotic cells. So, our results suggest that apoptosis 
induced by BCNU is mostly due to initial MGMT inhibition and may occur independently of the 
MMR system. 
 
4.5. Role of p53 tumor suppressor gene on induction of DNA damages and 
apoptosis by alkylating agents 
 
It is accepted that the levels of the tumor suppressor p53 gene plays a relevant role in 
several steps of the carcinogenic process as well as in the prognosis and response of cancer 
cells to chemotherapy (Ferreira et al., 1999).  
Therefore, in this part of work, we intended to explore the involvement of the p53 tumor 
suppressor on DNA damage and induction of cell death by apoptosis in colorectal cancer cells 
treated with TMZ or BCNU. For this, we used for comparison two isogenic HCT116 colon 
carcinoma cells showing different status of p53: cells with p53 wild type (p53-wt) and cells 
knockout for p53 tumor suppressor (p53-null).   
The results obtained for HCT116 p53-null cells (Figure 4.6 – A) demonstrated that the 
initial damages (after 1h of incubation) induced by TMZ or O6-BG plus TMZ decreased 
progressively during the 72h of experiment. In addition, it is observed that after 72h the values of 
percentage of DNA in tail, in both conditions (TMZ or O6-BG plus TMZ), were analogous to control 
values. The values obtained for control cells and cells pre-treated with O6-BG alone remained low. 
Through these results obtained with p53-null cell line, it can be suggested that the effects 
of methylating agents are MMR-dependent and, when MMR system is not functional, the 
functional status of p53 has no effect on extent of DNA damage induced by alkylating drugs to 
these cells. 
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At 1h of incubation, also in this cell line, treatment with BCNU (Figure 4.6 – B), increased 
significantly levels of DNA damage regardless of the presence of O6-BG. In the case of cells that 
were pre-incubated with MGMT inhibitor followed BCNU treatment, the DNA damages detected 
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Figure 4.6 - Effect on DNA damage induced by (A) TMZ and (B) BCNU in the presence or absence of O6-BG was 
evaluated by the comet assay on HCT116 p53-null cells. The cells were pre-incubated, during 2 hours, with or 
without O6-BG (100µM) before TMZ (200µM) or BCNU (100µM) treatment for 1, 48 and 72h. For each condition 
were performed three independent experiments and data are expressed as mean ± SEM.  Significant differences (*P 
< 0.05), determined by Student t-test, were found between cells with and without pre-treatment with O6-BG at 48h 
and 72h. One-way ANOVA followed by Tukey’s Multiple comparison test, showed statistically significant differences 
over time between cells without pre-treatment with O6-BG (# P < 0.05; ## P<0.01; ### P< 0.001) compared with 1h 
of treatment. 
(A) 
(B) 
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by comet assay remained elevated along the experiment. Contrarily, in cells treated with BCNU 
only, we found that, at 72h of experiment, the percentage of DNA damage induced by BCNU was 
significantly decreased and, significant differences were found compared with cells pre-incubated 
with O6-BG. No significant alterations in percentage of DNA damages were detectable by comet 
assay in the case of control cells and in cells pre-treated with O6-BG without chloroethylating 
agent incubation.  
Further, we decided to evaluate the contribution of p53 tumor suppressor for the induction 
of apoptosis by TMZ and BCNU through the nuclear condensation assay.   
In HCT116 p53-null cells (Figure 4.7 - A) there was no significant induction of apoptosis in 
cells with O6-BG pre-incubation followed TMZ treatment. The same pattern for the induction of 
apoptosis was obtained for cells incubated with TMZ only. The values obtained for this assay in 
both conditions were similar to respective controls. 
As expected, no variations in percentage of apoptotic cells were detected in control cells 
and in cells pre-treated only with O6-BG. 
It was verified that, contrarily to TMZ, incubation of HCT116 p53-null cells with BCNU only 
(Figure 4.7 – B) leads to a significant increase in number of apoptotic cells along the 96h of 
experiment. However, when cells were subjected to O6-BG pre-treatment followed by exposure to 
BCNU agent there was a similar pattern in percentage of apoptotic cells. No significant 
differences were detectable, at 96h of incubation, by nuclear condensation assay in untreated 
cells and cells pre-treated with O6-BG without BCNU agent. Therefore p53 seems to be required 
for induction of cell death mediated by O6-chloroethylating agents. 
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4.6. Effects of some phytochemicals on MGMT protein expression 
As already referred, modulation of DNA repair may be assumed to have a relevant role 
both in the prevention of DNA damage and mutations that may lead to genomic instability and 
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Figure 4.7 – Effect on induction of apoptosis, in HCT116 p53-null cells, by (A) TMZ (200µM), O6-BG (100 µM) 
or O6-BG plus TMZ and (B) BCNU (100µM), O6-BG (100 µM) or O6-BG plus BCNU. Apoptosis was evaluated 
through nuclear condensation assay at 48, 72 and 96h of treatment. For each condition were performed three 
independent experiments and data are expressed as mean ± SEM. Significant differences were found, by One-way 
ANOVA followed by Dunnett’s Multiple comparison test, when compared with respective control (untreated cells) 
(* P<0.05; ** P < 0.01). 
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cancer as well as on sensitivity to chemotherapeutic drugs. For instance, an increase of MGMT 
activity is expected to be a successful chemoprevention strategy. On the other hand, 
phytochemicals that cause downregulation of this protein can be important to patients 
undergoing chemotherapy with alkylating agents since this may help improve the effectiveness of 
the chemotherapeutic agents (Niture et al., 2006a).  
We assessed the effects of some natural compounds on MGMT protein expression in Caco-
2. For that, after 48h of incubation, the protein levels were monitored by western blot (β-actin 
antibody was used as loading control). As shown in Figure 4.8, no significant differences on 
MGMT protein levels are observed in Caco-2 cells between controls and cells incubated with 
tested phytochemicals (UA, Lut, Q, Curc, Sil, Resv, Rut and AO).  
The phenolic acid, rosmarinic acid at 50µM, reduced significantly the expression levels of 
MGMT protein comparatively with untreated cells. The other phytochemicals had no significant 
effects on MGMT protein levels. 
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Figure 4.6 – Effect of 48h of incubation with phytochemicals on MGMT protein expression, in Caco-2 cells. The 
protein levels were evaluated by Western Blot. As loading control, we used β-actin. For each condition three 
independent experiments were performed and data are expressed as mean ± SEM. Significant differences were 
found, by Student t-test, when compared with control (untreated cells) (* P<0.05). 
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Tumors of the colon and rectum (CRC) comprise a large number of cancers and are 
responsible for many deaths. The significant resistance to several drugs used in treatment of this 
type of cancer contributes to the low life expectancy of many CRC patients, a problem that 
requires new effective drugs and cheap and reliable methods to test them. 
Human cells are constantly exposed to DNA damaging agents that are produced 
endogenously (such as ROS and replication errors) or widely present in the environment which 
make an important contribution to tumor development. The most important effect of DNA 
damage is that, without proper repair, they may lead to the accumulation of mutations, genomic 
instability and cancer.  
Due to their cytotoxic effects some alkylating agents are frequently used as 
chemotherapeutic drugs, with the aim to induce DNA damage and cancer cell death. Based on 
this, a complete understanding of the cellular elements that determine the biological response to 
alkylating agents is relevant not only for cancer prevention but also to enhance the efficiency of 
cancer therapy. The two alkylating agents that were used in the present study, TMZ and BCNU, 
may cause alkylated base lesions in the DNA template, such as O6-alkylG lesions (O6meG and O6-
ClethG, respectively) and N-alkylated lesions (N1 and N7 positions of guanine). Consequently, 
these DNA lesions can be repaired by some DNA repair pathways (mainly by direct repair MGMT, 
MMR, BER, NER and HR systems) in an attempt protect from genotoxicity and mutagenesis (Fu 
et al., 2012). Cell death by apoptosis is the desired cellular response after the application of 
chemotherapeutic alkylating agents to cells. If the DNA lesions are not repaired, they may lead of 
blockage of DNA replication process causing stalling of replication forks and DSB formation that 
signal to cell death. Apoptosis following DNA damage have a protective role preventing the 
mutagenic or carcinogenic events. In addition, deficiencies in the activation of apoptotic response 
increase cancer incidence and, cause resistance of tumor cells when chemotherapy based on 
alkylating agents is applied.  
As referred before, also the DNA repair pathways modulate the sensitivity/resistance to 
alkylating agents. The MGMT protein has an important role on repair of initial O6alkylG lesions 
induced by both methylating and chloroethylating agents and, therefore, while playing an 
important role in cancer prevention, MGMT also constitutes the major mechanism of resistance 
to alkylating chemotherapeutic agents. Therefore, the inhibition of MGMT using pseudosubstrates 
(namely, O6-BG) improves the effectiveness to chemotherapy in cancer cells (Ramos et al., 2013; 
Verbeek et al., 2008).  In agreement with this, our results show that, the isolated application of 
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TMZ or BCNU reduced significantly the cellular viability. However, the combination of O6-BG with 
either of the two alkylating agents increased the effectiveness of the therapeutic agent since it 
reduced drastically the number of viable cells when compared with respective control cells 
(untreated cells). O6-BG, therefore, potentiated TMZ and BCNU cytotoxic effects. 
Some already available methodologies allow the quantification of MGMT repair activity 
(Christmann et al., 2011). However, the development of low cost and non-radioactive strategies 
is still necessary. The comet assay is a simple and low-cost method used for the assessment of 
DNA damages. Frequently, this method is used for measure the oxidative DNA damages as well 
as to evaluate the DNA effects of some natural compounds (chemoprevention). However, 
alkylating damages are more relevant both in terms of carcinogenesis and in the induction of cell 
death during cancer therapy. In a previous study (Ramos et al., 2013), the comet assay was 
used to evaluate the O6meG lesions caused by MNU in MGMT-inhibited and MMR-proficient cells. 
Here, we tested a new application for the comet assay with regard to estimate of both levels of 
O6meG as well as O6ClethG induced by alkylating agents. TMZ and BCNU were used in the 
presence or absence of O6-BG and the conversion of O6-alkylations into strand breaks by MMR-
proficient cells. The concentration of O6-BG used that inhibited MGMT was previously defined 
(Ramos et al., 2013). The results obtained in the present study not only confirm that the comet 
assay can be used to detect O6meG, as described previously by our group (Ramos et al., 2013), 
but also show the detection of O6ClethG lesions induced by chloroethylating agents. As observed 
in figure 4.2 – A and B, when cells were incubated only with TMZ or BCNU agents respectively, 
DNA damages were almost completely repaired by the second cycle of replication of Caco-2 cells 
(at 72h). This is expected because MGMT removes efficiently both initial O6meG or O6ClethG 
lesions introduced in the DNA template. MGMT efficiently transfers the alkyl group introduced in 
DNA base to the cysteine residue present in its active site (Kaina et al., 2010). However, when 
MGMT is inhibited by the application of O6-BG the comet assay detected high levels of DNA 
damages during the 72h of incubation because unrepaired O6ClethG or O6meG remained in the 
DNA template and are converted to strand breaks (SBs) through to the recognition and action of 
other proteins that belonging to DNA repair pathways such as MMR and NER during the cell 
replication (Kaina et al., 2007; Kondo et al., 2010b). Cells treated with O6-BG plus TMZ 
treatment, demonstrated an increase in DNA damage at 72h. This effect was not present at 48h 
because Caco-2 cells have very slow replication cycles and, O6meG lesions require two cell cycles 
to be converted into strand breaks. For both alkylating agents with or without the presence of O6-
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BG, at 1h of incubation, significant DNA damages were observed and, correspond to the initial 
damages (namely AP sites and SSBs) caused by BCNU and TMZ. This fact was in accordance 
with previous studies that used the methylating agent MNU (Ramos et al., 2013). For instance, 
BCNU is a chloroethylating agent that besides the O6ClethG lesions also induces N7-alkylG and 
N1-alkylG (Cui et al., 2009). These N-alkyl lesions are recognized and efficiently removed from 
DNA template by the BER system (Stojic et al., 2004). The MPG, a glycosylase that belongs to 
BER system, promotes the hydrolysis of the N-glycosylic bond (after and before of lesion site) 
which leads to the formation of AP sites (Maynard et al., 2009; Robertson et al., 2009). These AP 
sites are converted in breaks (Hegde et al., 2008) which allows their detection by the comet 
assay. However, their complete repair is carried out by other enzymes involved in BER pathway 
and, their contribution to total damage decreases rapidly due to efficient repair by BER. In 
agreement with this the methylating agent TMZ, produced similar results after 1h of incubation 
since this drug leads to the formation of monoadducts such as N7meG and N3meG besides the 
O6meG (Zhang et al., 2012). Again, these lesions are repaired by recognition and removal 
through the activation of BER system that leads to AP site formation.  
Because DNA strand breaks (detected by the comet assay) are potent inducers of cell death by 
apoptosis (Quiros et al., 2010), we decided to quantify apoptotic cell death induced by TMZ and 
BCNU with or without pre-incubation with MGMT inhibitor, O6-BG. Results showed that after 96h 
of incubation with TMZ and 72 and 96h of incubation with BCNU (Figure 4.3 – A and B) there 
was also a significant increase in apoptotic cell death in MGMT inhibited cells. Therefore, our 
results are in agreement with the findings previously described by others, since, in the case of 
TMZ, if the MGMT enzyme does not repair all O6meG lesions (due to, for instance, the inhibition 
of MGMT through pseudosubstrates), these lesions mispair with thymine, during replication 
process forming O6meG-T mismatches. This damage is recognized by MMR proteins that promote 
the removal of thymine from complementary strand. However, as long as O6meG remains in one 
the DNA template, thymine is again inserted and the MMR process will be repeatedly activated, 
resulting in a futile repair cycle. The recognition by MMR creates single strand breaks in the 
newly DNA strand that are accumulated and become cytotoxic after some replication cycles 
(Kaina et al., 2010). After two rounds of replication DSBs may eventually arise (Ochs and Kaina, 
2000; Quiros et al., 2010) and they are considered potent activators of the apoptosis (Quiros et 
al., 2010; Verbeek et al., 2008). After incubation of cells with O6-BG plus BCNU, the O6ClethG 
lesion, an unstable monoadduct also repaired by MGMT remains in the DNA template and is 
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converted into N1-O6-ethanoguanine (N1-O6EtG) that is capable to react with cytosine present in 
complementary strand forming a N1-guanine-N3-cytosine interstrand crosslink. If ICLs are not 
repaired, through to the repair proteins involved in NER system (Batista et al., 2007), they will 
lead to the formation of DSBs, upon replication, that induce cell death by apoptosis (Figure 5.1) 
(Kaina et al., 2010; Roos and Kaina, 2006). 
 
 
 
 
 
 
 
 
 
 
Significant apoptotic cell levels that were detected only after 96h of incubation with O6-BG 
plus TMZ treatment are in accordance with other groups’ observations. The processing of O6meG 
lesions into DSBs requires two replication cycles while   the induction of apoptotic process only 
occurs in subsequent cell replication cycles (Quiros et al., 2010). Another study also 
demonstrated that, in glioma cells that, O6meG triggers apoptosis after 120h of incubation 
requiring extensive cell proliferation (Roos et al., 2007). Non-significant levels of apoptosis were 
induced by the methylating (TMZ) and chloroethylating (BCNU) agents alone (Figure 4.3 – A and 
B, respectively) since, as mentioned before, MGMT efficiently repairs O6meG and O6-ClethG initial 
lesions from DNA template and consequently there is no formation of breaks in DNA and hence 
the apoptotic process was not triggered.  
Figure 5.1 – Repair of O6meG and O6ClethG lesions is executed by direct action of MGMT. In the absence of MGMT 
or under MGMT inactivation by O6-BG, these lesions not are removed from the template and eventually result in 
DSBs formation that are potent inducers of apoptosis. For apoptosis occurs in TMZ needs that MMR system 
recognizes DNA lesions and converted them into SBs. On the other hand, chloroethylating agents lead to the 
formation of ICLs that blocks the replication process causing cell death independently of MMR (Adapted from (Kaina 
et al., 2010)).  
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In conclusion, this Cometh methodology allows the assessment of alkylating DNA damages as 
mentioned before thereby being useful for the screening of new chemotherapeutic drugs that 
depend on the activity of MGMT protein. In addition it allows the test of other MGMT inhibitors. 
On the other hand, we verify that the application of O6-BG improves the effectiveness therapeutic 
of the O6-alkylating agents sensitising colorectal cancer cells to cell death. This study also 
suggested that the methylating and chloroethylating agents induced apoptotic cell death in an O6-
alkylG- dependent manner. 
 
Effect of mismatch repair system on DNA damage and induction of apoptosis 
by alkylating agents 
During the past years, several experiments have evidenced that mismatch repair 
mechanism are implicated in the cellular response to methylating agents. It has been described 
that O6meG does not have the ability to trigger cell death directly. For this, the activation of MMR 
system is required and MMR-deficient cells have demonstrated to be highly resistant to killing by 
SN1-type alkylating agents, such as MNNG and TMZ (Hickman and Samson, 1999; Ochs and 
Kaina, 2000; Pepponi et al., 2003). However, the contribution of mismatch repair system in 
chemoresistance to chloroethylating agents (such as BCNU) is still unclear and more studies are 
required its complete understanding. Therefore, in this part of work we decided to analyze the 
contribution of MMR system for the recognition of O6-alkylG lesions and their conversion to SBs. 
To this end, we measured the DNA damage (Figure 4.4 – A and B) induced by TMZ and BCNU 
by a CoMeth assay and quantified apoptotic cell death (Figure 4.5 – A and B) using a MMR-
deficient cell line (HCT116). We demonstrated that, in HCT116 cells, after 72h of incubation with 
TMZ or O6-BG plus TMZ (Figure 4.4 - A) the values obtained for DNA damages were similar to 
those obtained for control cells (DMSO only). Comparatively with above results, the Caco-2 MMR-
proficient cells exhibited significant high levels of DNA damage at 72h after incubation of O6-BG 
plus TMZ agent (Figure 4.2 – A).  As expected, in HCT116 cells the comet assay did not detect 
O6meG lesions because they were not transformed into SBs due to the presence of a defective 
MMR system. In opposition of Caco-2 cells (Figure 4.3 – A), induction of apoptosis did not occur 
in HCT116 cells even in the presence of MGMT inhibitor O6-BG (Figure 4.5 - A). The reason is 
that O6meG:T mispairs were not recognized by MMR system and formation of SBs did not occur 
thereby not triggering cell death by apoptosis. These results corroborate with studies performed 
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previously by our group using MNU methylating agent (Ramos et al., 2013). Taken this into 
account, it is possible infer that, MMR-deficient cells (HCT116) were resistance to TMZ therapy 
compared to the MMR-proficient cell line Caco-2. With regard to cell death results, the same 
observation had already been made by Noonan and collaborators since they demonstrated that 
TK6 cells (MGMT – and MMR – deficient) did not exhibit significant levels of apoptotic cells 
following high doses of MNNG treatment when compared with TK6 MGMT- and -MMR proficient 
cells (Noonan et al., 2012). A possible mechanism is that, in response to DNA damage induced 
by methylating agents, human MutSα (MSH2/MSH6) and posteriorly MutLα (MLH1/PMS2) are 
recruited, bind and efficiently recognize O6meG:T mispairs and, consequently, promote the 
recruitment of ATR to DNA  lesion sites with activation of ATR kinase resulting in phosphorylation 
of the downstream targets (such as Chk1) (Yoshioka et al., 2006) that trigger several DNA 
damage responses (DDR) including apoptosis (Jackson and Bartek, 2009). The authors refer that 
recruitment and activation of several DDR network proteins occurs in a manner that is dependent 
the presence of a proficient MMR system (Yoshioka et al., 2006). Recently, two models have 
been proposed that demonstrate the connection between the MMR system and methylating agent 
sensitivity (Figure 5.2): a direct signaling model and indirect futile repair model. In the direct 
signaling model the recognition and binding of O6meG:T mismatches by MMR proteins (MutSα 
and  MutLα) leads to the direct activation of key DNA damage signaling kinases (such as ATR 
kinase), that in the presence of high levels of these mismatches trigger cell death by apoptosis. 
The indirect futile repair model proposes that repeated cycles of recognition, excision of the 
lesion and reinsertion of thymine nucleotide in new DNA strand at O6meG:T mismatches sites, 
due to the action of MMR pathway, leads to futile repair cycles and occurrence of SSBs. These 
SSBs function as an additional substrate for indirect signaling activation. After 2 replication cycles 
these breaks cause stalled replication forks and consequently lead the formation of DSBs. These 
events culminate in DDR network activation that promote the phosphorylation of a number of 
proteins involved, namely ATM, ATR, Chk1 and p53  and induction of apoptotic cell death 
(Noonan et al., 2012). 
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On the other hand, with regard to BCNU treatment there is controversy about the 
dependence of the MMR system for cytotoxic effects. There are experiments that suggested that 
MMR system, although weakly, also is involved in the protection of the melanoma cell lines 
against BCNU treatment (Pepponi et al., 2003). On the contrary, Cui and collaborators 
demonstrated that DNA damage response caused by BCNU treatment was independent of the 
functional MMR system status (Cui et al., 2009).  
Our results demonstrated that, when BCNU treatment is applied to MMR-deficient cells 
(Figure 4.4 - B) DNA damages were gradually decreasing during the subsequent 72h of 
incubation, because, as referred above, MGMT efficiently repaired O6ClethG lesions from the DNA 
template. As expected, low levels of apoptotic cells were detected in this condition over the entire 
time of experiment (Figure 4.5 - B). However, when MMR-deficient cells were pre-incubated with 
O6-BG, for MGMT inhibition, there were high significant levels of DNA damages at 72h, as also 
observed above for the case of MMR-proficient Caco-2 cells (Figure 4.2 - B). The unrepaired O6-
ClethG lesions remain in the DNA strand and rapidly react with cytosine and interstrand 
crosslinks (ICL) are formed. This leads to the blockage of DNA replication machinery and the 
Figure 5.2 – Two models proposed by interaction between MMR system and sensitivity of methylating agents. A 
direct signaling model (left) and indirect futile repair model (right) may work simultaneously in order to mediate the 
cellular response to methylating agents (from (Noonan et al., 2012)). 
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DSBs are created after one cycle of replication (Figure 5.1) (Kaina et al., 2010). As observed in 
MMR-proficient Caco-2 cells (Figure 4.2 - B), in the presence of O6-BG plus BCNU the percentage 
of apoptotic cells was significantly higher compared with control cells (Figure 4.5 - B). By 
comparing the Caco-2 and HCT116 cells is possible to suggest that the cytotoxic effects induced 
by BCNU treatment are independent of functional status of MMR system. Recently in a study with 
medulloblastoma cell lines, it was proposed that DNA interstrand crosslinks are the main 
responsible for activation of the DDR pathway that culminate in ATR-Chk1 activation (Cui et al., 
2009) triggering eventually apoptotic cell death (Kaina et al., 2010). In conclusion, cytotoxicity 
induced by BCNU may occur in an MMR - independent manner.  
In conclusion, the application of BCNU treatment in tumors that have microsattelite instability 
(MSI) due to the loss of MMR system may be a good alternative to the use of TMZ. 
 
Effect of p53 tumor suppressor on DNA damage and induction of apoptosis by 
TMZ and BCNU agents 
The p53 tumor suppressor has a prominent role in keeping genomic integrity and 
preventing cancer development. As “guardian of the genome”, its major functions are to regulate 
the apoptosis and cell growth (Menendez et al., 2009). Upon genotoxic stresses, such as cancer 
treatment based on chemotherapeutic drugs, this protein is activated leading to its translocation 
to nucleus and transcription of target genes (Chari et al., 2009). However, as mentioned before, 
there is controversy about the role of p53 in cancer chemotherapy. We intended to clarify the 
involvement of p53 on DNA damage and induction of apoptosis in colorectal cancer cells in 
response to alkylating chemotherapeutic agents. For that, we compared two isogenic cell lines – 
HCT116 p53-wt and HCT116 p53-null. The initial DNA damage detected after TMZ treatment 
was decreasing over time, in HCT116 p53-null cells, even in the presence of O6-BG (Figure 4.6 - 
A), and consequently without induction of cell death by apoptosis (Figure 4.7 - A). As previously 
demonstrated, similar results were obtained with p53-wt HCT116 cells since also in this cell line 
no significant increase were found in number of apoptotic cells at 96h of treatment (Figure 4.5 - 
A). These results allow us to suggest that TMZ cytotoxic effects are independent of p53 status 
whereas requiring a functional MMR system. In our study, even in the presence of p53-wt, MMR-
deficient cells were not capable to activate the apoptotic process because there was no 
recognition of the O6meG:T mismatches by MutSα and MutLα proteins. This way, as suggested 
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by Noonan group that used TK6/MGMT proficient and TK6/MMR deficient cells (Noonan et al., 
2012), ATR-Chk1 signaling pathway is not activated and low levels of phosphorylation of Chk1 
and p53 were detected. In general, the treatment with methylating agents results in the 
phosphorylation of p53, however, these phosphorylation depends on the presence of functional 
MutSα and MutLα proteins in the DNA lesion site (Duckett et al., 1999). 
In the case of BCNU treatment, in both cell lines studied (HCT116 p53-wt Figure 4.4 – B 
and HCT116 p53-null Figure 4.5 - B) it has verified that in presence of O6-BG, BCNU incubation 
results in a high levels of DNA damages over time independently of the presence of functional 
p53 protein. Therefore, these results suggest that the O6ClethG lesions remain in DNA template 
forming interstrand crosslink. These ICLs, during the G1 phase of cell cycle are recognized and 
removed through to nucleotide excision repair. However, if this O6ClethG lesion cannot be 
repaired its conversion in DSBs occurs (Deans and West, 2011) allowing the detection by comet 
assay. 
The observations based on nuclear condensation assay showed that BCNU induced 
apoptosis both in HCT116 p53-wt (Figure 4.5 - B) and HCT116 p53-null cells (Figure 4.7 – B). 
These results are in agreement with the DSB detected by comet assay. However, when both cell 
lines were subjected to O6-BG pre-treatment followed BCNU were found some differences 
between the two cell lines. It is observed that p53-wt cells were more sensitive than p53-null cells 
to apoptosis since a higher percentage of apoptotic cells were observed when p53 was 
functional. Our results are in accordance with other in glioma cells (Hermisson et al., 2006). The 
induction of apoptosis in both cases is presumably due to the fact that p53-null cells trigger cell 
death independently of p53 transcriptional activity (Goldstein et al., 2008). Therefore, our results 
may suggest that O6ClethG lesion, just like O6meG (Kaina et al., 2007), may evoke the two 
apoptotic pathways – mitochondrial- or -extrinsic apoptotic pathway (Fas/CD95/Apo-1) 
depending on p53 functional status. However, this hypothesis needs to be clarified in subsequent 
studies in colorectal cancer cells. 
 For instance, after O6-ClethG lesion formation it was verified in previous studies that 
glioma cells with mutated p53 gene trigger the activation of mitochondrial apoptotic pathway 
(Batista et al., 2007) with cells exhibiting a decline in anti-apoptotic Bcl-2 protein levels leading to 
the release of cytochrome c from mitochondria. This release activates Bax and Bak pro-apoptotic 
proteins and pro-caspase 9. Meanwhile, this pro-caspase promotes the activation of the effector 
caspases, such as caspase 3 and 7 (Hector and Prehn, 2009). On the other hand, the same 
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study also revealed that in cells with wt-p53, O6-ClethG lesions lead to the activation of both 
extrinsic apoptotic pathway (by stimulation of death receptor on the cell membrane, FasR) and 
the intrinsic apoptotic pathway (Batista et al., 2007). In this pathway, the FasR and its respective 
ligand (FasL) promote the induction of caspase-8 which in turn activates their effector caspases 
(such as caspase 3) (Hector and Prehn, 2009). This is also in line with some other studies with 
methylating treatment, where wt-p53 cells underwent apoptosis through the extrinsic apoptotic 
pathway (Dunkern et al., 2003; Roos et al., 2004; Roos et al., 2007) and in p53 mutated cells 
where there was the activation the mitochondrial apoptotic pathway (Figure 5.3) (Ochs and 
Kaina, 2000; Roos et al., 2007). 
 
 
 
 
 
 
 
 
Due to the role of p53 in chemosensitivity will be fundamental to explore if the same 
apoptotic behavior dependent on p53 status, demonstrated in glioma cells, also applies to 
colorectal cancer cells.  
Therefore, the determination of p53 status in tumors will be useful to predict the response 
to alkylating agents in colorectal cancer patients.  
 
 
 
Figure 5.3 – Apoptotic pathways triggered by O6-alkylG lesions in cancer cells with wildtype p53 (left panel) or 
with mutated p53 tumor suppressor (right panel) (Adapted from (Kaina et al., 2007)). 
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Impact of natural compounds on MGMT protein expression 
MGMT is very relevant since it performs not only functions in cancer response to 
chemotherapy based on alkylating agents but also function in cancer prevention. Dietary natural 
compounds that promote an increase of MGMT activity levels may be useful in terms of 
chemoprevention. In turn, downregulation of MGMT activity through the use of natural 
compounds may be beneficial for cancer therapy based on alkylating agents. Our results of 
natural compounds on expression of MGMT by western blot showed that rosmarinic acid (RA) 
may contribute to increase the cytotoxicity induced by alkylating agents since it induced a decline 
in MGMT expression levels (48h of incubation with RA (50µM)) (Figure 4.8).  
Although this still needs to be verified, daily consumption of RA may be beneficial when patients 
are subjected to cancer therapy based on alkylating agents, since it might raise treatment 
efficacy and may be reduce the side effects associated with therapy. 
 
Concluding remarks 
With this project it was possible demonstrate that the comet assay (CoMeth) also can be 
efficiently used to assess alkylating DNA damages, O6ClethG, induced by chloroethylating agents, 
BCNU in addition to O6meG induced by TMZ. It was possible to observe that the pre-incubation of 
cells with MGMT inhibitor, O6-BG, potentiates the cytotoxic effects caused by these two alkylating 
agents. This method will allow test new MGMT inhibitors, evaluate the potential effects of other 
chemotherapeutic agents that depend by the action of MGMT activity. Furthermore, it will may 
also allow testing compounds (for instance, demethylating agents) that enhance the expression of 
MGMT and MMR genes (that are often epigenetically silenced in several tumor types).  
We found that for methylating agents exert their cytotoxic effects in cancer cells they 
require the presence of a functional MMR system for conversion of O6meG lesions into strand 
breaks (detected by the comet assay when MGMT is inhibited). When this DNA repair system not 
is functional, cancer cells showed a higher resistance to TMZ treatment since apoptosis did not 
occur. Therefore, CRC MSI patients need alternative treatment that based on drugs that do not 
require the functional status of MMR system. Contrary, the obtained results suggest that DNA 
damages and cell death by apoptosis induced by BCNU occurs in an MMR-independent manner. 
We can suggest that the application of BCNU to patients with microsatellite instability (MSI) due 
to loss of MMR system may be a good alternative for therapeutic strategy. 
5. Discussion and Conclusions 
 70  
 
We then investigated the influence of p53 status in sensitivity to alkylating drugs by 
comparing effects in two isogenic cell lines, HCT116 p53-wt and the same line knockdown for 
p53 (HCT116 p53-null). The results suggest that the absence of p53 tumor suppressor gene 
attenuates BCNU cytotoxicity (lower percentage of apoptotic cells), when O6-BG was applied on 
colorectal cancer cells and did not improve the response to TMZ in MMR deficient cells. 
Collectively, the determination of p53 status as well as MMR will help to identify CRC patients 
which will be more susceptible to particular alkylating anticancer agents.  
In terms of the diet, a phenolic compound present in plants, rosmarinic acid (RA), 
decreased the MGMT protein expression levels and may be important to cancer chemotherapy 
based on drugs that depend on the action of direct repair by MGMT. 
Although more studies are needed, this result may indicate that the consumption of this 
compound during the chemotherapeutic process can enhance the efficiency of alkylating 
compounds. 
CoMeth is a useful tool in the test of new chemotherapeutic compounds such as alkylating 
agents, MGMT inhibitors, p53 regulators, MMR inducers (epigenetic drugs). This cheap and 
versatile method may also use in nutraceutic research allowing to test chemopreventive natural 
compounds or other that improve chemotherapeutic sensitivity. 
 
Future perspectives 
With this study, we found that methylating (TMZ) and chloroethylating (BCNU) agents 
induced DNA damages that are detected by the new methodology previously developed in our 
group. These lesions after the intervention of some DNA repair systems are converted in DSBs 
that may culminate in cell death by apoptosis. For comprove the results, in future work, we would 
compared the effects 5-fluoropyrimidine 5-fluorouracil (5-FU) and Oxaliplatin, that are the 
standard therapies applied in cases of CRC patients, and their dependence of MMR system for 
caused DNA damages, using comet assay, and apoptotic cell death. 
Another topic that would be interesting to investigate is concomitant application of natural 
compounds and alkylating agents in colorectal cancer cells. Considering the potential effects of 
dietary compounds on cancer prevention, studies that evaluate the role of diet during 
chemotherapy process are needed. Therefore, will be interesting try to understand if the 
consumption of dietary compounds influences the response of colorectal cancer cells when is 
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being treated with alkylating agents. For that, parameters such as DNA damage, by comet assay, 
and cell death by apoptosis, using nuclear condensation assay, would be evaluated. 
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In order to define the adequate concentration that are able to reduce the cell viability to 
about 50% was performed a MTT assay. Cells were treated with TMZ (Figure 1- A) or BCNU 
during 24, 48 and 72h with defined concentrations (range between 1µM - 200µM).  
  
  
Supplementary Figure 4.3 – Dose dependent influence on cellular viability in Caco-2 cells of (A) TMZ and (B) 
BCNU, by MTT assay. Different concentration of TMZ and BCNU were incubated in cells after 24, 48 and 72h. 
Each condition represents mean ± SEM for three independent experiments. Significant differences, determined 
through Student’s t-test, were found compared with control cells (*P < 0.05; *** P < 0.001). 
 
 
co
nt
ro
l M
1
M

10
M

50
M

10
0
M

20
0
co
nt
ro
l M
1
M

10
M

50
M

10
0
M

20
0
co
nt
ro
l M
1
M

10
M

50
M

10
0
M

20
0
0
50
100
150 24h 48h 72h
BCNU
*
**
**
***%
 C
el
l v
ia
bi
lit
y
co
nt
ro
l
1m
M
10
m
M
50
m
M
10
0m
M
20
0m
M
co
nt
ro
l M
1
M

10
M

50
M

10
0
M

20
0
co
nt
ro
l M
1
M

10
M

50
M

10
0
M

20
0
0
50
100
150 24h 48h 72h
TMZ
**
%
 C
el
l v
ia
bi
lit
y
(B) 
(A) 
7. Annexes 
 86  
The results demonstrated that cell viability decreased with increasing concentrations of 
TMZ (supplementary Figure 3.1 – A) and BCNU (supplementary Figure 3.1 – B) in Caco-2 cells. 
The Caco-2 cells seem to be more susceptible to methylating agent only after 72h where there is 
a reduction of 50% in cell viability. The same conclusion can be applied for case of BCNU agent.  
 
Lysis buffer for comet assay 
To prepare one liter of Lysis buffer, 1.211g of Tris Base (10mM), 146.1g of NaCl and 
37.22g of Na2EDTA were dissolved in 850ml of water. Posteriorly, the pH is adjusted to 10 using 
NaOH. To complete the buffer solution, it is also necessary to add 1% (v/v) of Triton X-100.  
Electrophoresis buffer for comet assay 
To prepare electrophoresis buffer is necessary dissolved, in 800ml of distilled water, 
100ml of NaOH (300mM) and 5mL of EDTA (200mM). After dissolution the volume was adjusted 
to 1L. 
 
 
 
